|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression decreases expression multiple interactions |
ISO |
Atorvastatin results in increased expression of ABCA1 mRNA Atorvastatin results in decreased expression of ABCA1 mRNA; Atorvastatin results in decreased expression of ABCA1 protein [Rosiglitazone co-treated with Atorvastatin] results in increased expression of ABCA1 protein |
CTD |
PMID:15183127 PMID:16386711 PMID:25278499 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Atorvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Atorvastatin results in decreased activity of ABCB11 protein |
CTD |
PMID:15901796 PMID:23956101 PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases expression decreases activity increases transport |
ISO EXP |
ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Atorvastatin]; Atorvastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM] Atorvastatin results in decreased expression of ABCB1A mRNA Atorvastatin analog results in decreased activity of ABCB1 protein ABCB1 protein results in increased transport of Atorvastatin; ABCB1 protein results in increased transport of Atorvastatin analog |
CTD |
PMID:10751037 PMID:15616150 PMID:19802823 PMID:24502637 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression |
ISO |
Atorvastatin results in increased expression of ABCB4 mRNA; Atorvastatin results in increased expression of ABCB4 protein |
CTD |
PMID:15986414 PMID:25278499 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases activity multiple interactions increases expression |
ISO EXP |
Atorvastatin analog results in decreased activity of ABCC2 protein ABCC2 protein binds to and results in increased uptake of Atorvastatin analog; Atorvastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Atorvastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM] Atorvastatin results in increased expression of ABCC2 mRNA |
CTD |
PMID:15616150 PMID:23562342 PMID:25278499 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
ISO |
Atorvastatin results in increased expression of ABCC3 mRNA; Atorvastatin results in increased expression of ABCC3 protein |
CTD |
PMID:15986414 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of ABCG2 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
ISO |
Atorvastatin results in increased expression of ABCG5 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
ISO |
Atorvastatin results in increased expression of ABCG8 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
increases expression multiple interactions |
EXP |
Atorvastatin results in increased expression of ACACB mRNA Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of ACACB mRNA] |
CTD |
PMID:12056585 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases expression |
EXP |
Atorvastatin results in decreased expression of ACE mRNA |
CTD |
PMID:23390189 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases expression |
EXP |
Atorvastatin results in increased expression of ACE2 mRNA |
CTD |
PMID:23390189 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:21122807 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of ACTA2 protein] |
CTD |
PMID:34939712 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adam12 |
ADAM metallopeptidase domain 12 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of ADAM12 protein |
CTD |
PMID:18360054 |
|
NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of ADAM17 protein |
CTD |
PMID:18360054 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ADGRE1 protein] |
CTD |
PMID:37023836 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression increases expression |
ISO |
Atorvastatin results in decreased expression of ADIPOQ protein Atorvastatin results in increased expression of ADIPOQ protein |
CTD |
PMID:19651449 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [AGT protein results in decreased expression of SOD1 protein]; Atorvastatin inhibits the reaction [AGT protein results in increased abundance of Malondialdehyde]; Atorvastatin inhibits the reaction [AGT protein results in increased activity of MAPK1 protein]; Atorvastatin inhibits the reaction [AGT protein results in increased activity of MAPK3 protein]; Atorvastatin inhibits the reaction [AGT protein results in increased expression of NOX1 protein] |
CTD |
PMID:19451411 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
increases expression |
ISO |
Atorvastatin results in increased expression of AKR7A2 mRNA; Atorvastatin results in increased expression of AKR7A2 protein |
CTD |
PMID:38484826 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
Atorvastatin inhibits the reaction [Homocysteine results in decreased phosphorylation of AKT1 protein] [Atorvastatin co-treated with Celecoxib] results in decreased phosphorylation of AKT1 protein; Atorvastatin results in decreased expression of and results in decreased phosphorylation of AKT1 protein Atorvastatin results in decreased phosphorylation of AKT1 protein Atorvastatin results in increased phosphorylation of AKT1 protein [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of AKT1 protein]; coenzyme Q10 inhibits the reaction [Atorvastatin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:18172863 PMID:19526287 PMID:20305681 PMID:27345130 PMID:27815113 PMID:29630879 PMID:32259528 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Angpt2 |
angiopoietin 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of ANGPT2 mRNA |
CTD |
PMID:16410222 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Apob |
apolipoprotein B |
multiple interactions decreases secretion decreases expression |
ISO EXP |
Atorvastatin results in decreased expression of and results in decreased secretion of APOB protein Atorvastatin inhibits the reaction [Fructose results in increased expression of APOB protein] Atorvastatin results in decreased secretion of APOB protein Atorvastatin results in decreased expression of APOB protein |
CTD |
PMID:9512650 PMID:10357840 PMID:11728391 PMID:12065722 PMID:12172771 PMID:12612140 PMID:12633795 PMID:18702965 More...
|
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
decreases expression multiple interactions |
ISO |
Atorvastatin results in decreased expression of APOE mRNA; Atorvastatin results in decreased expression of APOE protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the activity of GPT protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of BAX protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of BCL2 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of CASP3 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of FTH1 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of GPX4 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of HMOX1 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of NFE2L2 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of RELA protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TFRC protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TRP53 protein] [Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with Atorvastatin co-treated with Valsartan] results in decreased expression of APOE protein |
CTD |
PMID:16386711 PMID:19603250 PMID:32976958 PMID:37121058 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [APP protein results in decreased expression of SLC1A2 protein]; Atorvastatin inhibits the reaction [APP protein results in decreased expression of SLC1A3 protein] |
CTD |
PMID:20816828 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of ATF6 protein] |
CTD |
PMID:34939712 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases response to substance |
ISO |
ATG5 mutant form promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; ATG5 mutant form promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein] ATG5 results in increased susceptibility to Atorvastatin |
CTD |
PMID:20876807 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of BAK1 protein |
CTD |
PMID:19935899 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Atorvastatin results in increased expression of BAX protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of BAX protein] |
CTD |
PMID:19935899 PMID:37121058 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
Atorvastatin results in decreased expression of BCL2 mRNA; Atorvastatin results in decreased expression of BCL2 protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of BCL2 protein] [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of BCL2 protein] 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in decreased expression of BCL2 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased expression of BCL2 protein] |
CTD |
PMID:16470222 PMID:31423616 PMID:32259528 PMID:37121058 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of BECN1 protein |
CTD |
PMID:20876807 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
ISO |
Atorvastatin results in increased expression of BGLAP mRNA |
CTD |
PMID:17252541 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
EXP |
Atorvastatin results in decreased expression of and results in increased cleavage of BID protein; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased expression of and results in increased cleavage of BID protein]; U 0126 inhibits the reaction [Atorvastatin results in decreased expression of and results in increased cleavage of BID protein] |
CTD |
PMID:18339080 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
EXP |
Atorvastatin results in decreased expression of BIRC5 mRNA; Atorvastatin results in decreased expression of BIRC5 protein |
CTD |
PMID:17372815 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases expression increases secretion |
ISO |
Atorvastatin results in increased expression of BMP2 mRNA Atorvastatin results in increased secretion of BMP2 protein |
CTD |
PMID:16470222 PMID:17252541 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
C3 |
complement C3 |
multiple interactions |
EXP |
[Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased activity of C3 protein modified form] |
CTD |
PMID:20946910 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of CASP1 protein] |
CTD |
PMID:34939712 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases activity decreases activity multiple interactions increases cleavage |
ISO EXP |
Atorvastatin results in increased activity of CASP3 protein Atorvastatin results in decreased activity of CASP3 protein [Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein]; U 0126 inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein] Atorvastatin results in increased cleavage of CASP3 protein [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the cleavage of CASP3 protein; ATG5 mutant form promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of CASP3 protein]; Atorvastatin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein] 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; [Atorvastatin co-treated with Celecoxib] results in increased cleavage of and results in increased activity of CASP3 protein; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein]; RHOA protein inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein] |
CTD |
PMID:16470222 PMID:18172863 PMID:18339080 PMID:19429019 PMID:20305681 PMID:20876807 PMID:20946910 PMID:30511338 PMID:31423616 PMID:37121058 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO EXP |
[Atorvastatin co-treated with Celecoxib] results in increased cleavage of CASP8 protein [Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased activity of CASP8 protein]; [Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased expression of CASP8 protein] Atorvastatin results in increased activity of CASP8 protein |
CTD |
PMID:15705602 PMID:18172863 PMID:20946910 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO EXP |
[Atorvastatin co-treated with Celecoxib] results in increased cleavage of CASP9 protein Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of CASP9 protein]; U 0126 inhibits the reaction [Atorvastatin results in increased activity of CASP9 protein] |
CTD |
PMID:15705602 PMID:16470222 PMID:18172863 PMID:18339080 PMID:29630879 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions increases activity |
EXP ISO |
Atorvastatin inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] Atorvastatin results in increased activity of CAT protein |
CTD |
PMID:17479860 PMID:25218292 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression |
ISO EXP |
Atorvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Atorvastatin results in decreased expression of and results in decreased secretion of CCL2 protein; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased expression of CCL2 mRNA] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of CCL2 protein]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of CCL2 protein] |
CTD |
PMID:12117737 PMID:25058445 PMID:34939712 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd14 |
CD14 molecule |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD14 protein |
CTD |
PMID:18333374 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO EXP |
Atorvastatin inhibits the reaction [Rosiglitazone results in increased expression of CD36 mRNA]; Atorvastatin inhibits the reaction [Rosiglitazone results in increased expression of CD36 protein] [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of CD36 protein] |
CTD |
PMID:15183127 PMID:16386711 PMID:32259528 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd40 |
CD40 molecule |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD40 protein |
CTD |
PMID:16387846 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd40lg |
CD40 ligand |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD40LG protein |
CTD |
PMID:16368305 PMID:19171469 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd83 |
CD83 molecule |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD83 protein |
CTD |
PMID:16387846 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cd86 |
CD86 molecule |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD86 protein |
CTD |
PMID:16387846 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdc42 |
cell division cycle 42 |
multiple interactions |
ISO |
[Poly I-C co-treated with Atorvastatin] results in decreased expression of CDC42 mRNA |
CTD |
PMID:34696514 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of CDH1 protein] |
CTD |
PMID:34939712 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[Atorvastatin co-treated with Celecoxib] results in increased expression of CDKN1A protein; CDKN1A protein mutant form inhibits the reaction [Atorvastatin results in increased cleavage of PARP1 protein] Atorvastatin results in increased expression of CDKN1A protein |
CTD |
PMID:18172863 PMID:20876807 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases expression |
ISO |
[Atorvastatin co-treated with Celecoxib] results in increased expression of CDKN1B protein Atorvastatin results in increased expression of CDKN1B protein |
CTD |
PMID:16470222 PMID:18172863 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Sodium Glutamate results in increased phosphorylation of CHUK protein] |
CTD |
PMID:19800637 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Clcn1 |
chloride voltage-gated channel 1 |
decreases expression |
EXP |
Atorvastatin results in decreased expression of CLCN1 protein |
CTD |
PMID:27377005 |
|
NCBI chr 4:71,171,949...71,201,483
Ensembl chr 4:71,172,547...71,199,984
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Atorvastatin results in increased expression of COL1A1 mRNA |
CTD |
PMID:17252541 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression multiple interactions |
EXP |
Atorvastatin results in increased expression of CPT1A mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin results in increased expression of CPT1A mRNA] |
CTD |
PMID:19053045 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crp |
C-reactive protein |
multiple interactions decreases expression |
ISO EXP |
[Atorvastatin co-treated with Amlodipine] results in decreased expression of CRP protein; Atorvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP mRNA]; Atorvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP protein] Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of CRP protein] Atorvastatin results in decreased expression of CRP protein |
CTD |
PMID:16025360 PMID:16360360 PMID:17673219 PMID:18389332 PMID:21584495 PMID:25058445 More...
|
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cs |
citrate synthase |
increases expression multiple interactions |
EXP |
Atorvastatin results in increased expression of CS mRNA Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of CS mRNA] |
CTD |
PMID:21775390 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of CSF2 mRNA]; Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of CSF2 protein]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of CSF2 mRNA]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of CSF2 protein] |
CTD |
PMID:19482827 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
decreases expression |
EXP |
Atorvastatin results in decreased expression of CXCL10 |
CTD |
PMID:15831368 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of CYBA mRNA] |
CTD |
PMID:25218292 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions affects localization |
EXP ISO |
[Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of CYCS protein] Atorvastatin affects the localization of CYCS protein 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin affects the localization of CYCS protein] |
CTD |
PMID:31423616 PMID:32259528 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
affects expression |
EXP |
Atorvastatin affects the expression of CYP11A1 mRNA |
CTD |
PMID:29574565 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
EXP |
Atorvastatin results in increased expression of CYP17A1 mRNA |
CTD |
PMID:29574565 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression |
EXP |
Atorvastatin results in increased expression of CYP19A1 mRNA |
CTD |
PMID:29574565 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression increases expression |
ISO |
Atorvastatin results in decreased expression of CYP27A1 mRNA; Atorvastatin results in decreased expression of CYP27A1 protein Atorvastatin results in increased expression of CYP27A1 mRNA |
CTD |
PMID:16386711 PMID:25278499 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
Atorvastatin results in increased expression of CYP2B6 mRNA Atorvastatin results in increased expression of CYP2B10 mRNA; Atorvastatin results in increased expression of CYP2B10 protein |
CTD |
PMID:15802384 PMID:15986414 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of CYP39A1 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases expression affects response to substance increases metabolic processing multiple interactions affects metabolic processing decreases activity increases expression |
EXP ISO |
Atorvastatin results in decreased expression of CYP3A4 mRNA; Atorvastatin results in decreased expression of CYP3A4 protein CYP3A4 polymorphism affects the susceptibility to Atorvastatin CYP3A4 protein results in increased metabolism of Atorvastatin ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Atorvastatin]; Atorvastatin inhibits the reaction [CYP3A4 protein affects the metabolism of Midazolam] CYP3A4 protein affects the metabolism of Atorvastatin Atorvastatin results in decreased activity of CYP3A4 protein Atorvastatin results in increased expression of CYP3A4 protein Atorvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 mRNA]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 protein] |
CTD |
PMID:15963098 PMID:16011971 PMID:16029222 PMID:18528690 PMID:18846481 PMID:19802823 PMID:26616219 PMID:30086269 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions |
EXP |
[Dietary Fats co-treated with Atorvastatin] results in increased expression of CYP3A23-3A1 protein |
CTD |
PMID:26616219 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases expression multiple interactions |
ISO EXP |
Atorvastatin results in increased expression of CYP7A1 mRNA Atorvastatin inhibits the reaction [Dietary Fats results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:25278499 PMID:32048413 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Dcx |
doublecortin |
increases expression |
EXP |
Atorvastatin results in increased expression of DCX protein |
CTD |
PMID:15255259 |
|
NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
increases expression multiple interactions increases activity |
EXP |
Atorvastatin results in increased expression of DGAT1 mRNA Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of DGAT1 protein] |
CTD |
PMID:12056585 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dscc1 |
DNA replication and sister chromatid cohesion 1 |
affects response to substance |
ISO |
DSCC1 protein affects the susceptibility to Atorvastatin |
CTD |
PMID:35926565 |
|
NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of EDN1 protein |
CTD |
PMID:16360360 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions decreases expression |
EXP |
Atorvastatin promotes the reaction [Losartan results in decreased expression of EDNRA mRNA]; Losartan promotes the reaction [Atorvastatin results in decreased expression of EDNRA mRNA] |
CTD |
PMID:23091284 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Phenylephrine results in increased expression of and results in increased phosphorylation of and results in increased activity of EGFR protein] |
CTD |
PMID:18360054 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases response to substance |
ISO |
EIF2AK3 mutant form inhibits the reaction [Atorvastatin results in increased phosphorylation of EIF2S1 protein] EIF2AK3 results in increased susceptibility to Atorvastatin |
CTD |
PMID:20876807 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
4-phenylbutyric acid inhibits the reaction [Atorvastatin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Atorvastatin results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:20876807 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Epb41 |
erythrocyte membrane protein band 4.1 |
multiple interactions |
EXP |
[Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in decreased expression of EPB41 protein] |
CTD |
PMID:20946910 |
|
NCBI chr 5:144,110,010...144,264,037
Ensembl chr 5:144,111,906...144,237,821
|
|
G |
F2 |
coagulation factor II, thrombin |
decreases activity |
ISO |
Atorvastatin results in decreased activity of F2 protein |
CTD |
PMID:16907931 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F5 |
coagulation factor V |
decreases activity |
ISO |
Atorvastatin results in decreased activity of F5 protein |
CTD |
PMID:16907931 |
|
NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
EXP |
[Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased expression of FADD protein] |
CTD |
PMID:20946910 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
affects expression |
EXP |
Atorvastatin affects the expression of FAS mRNA; Atorvastatin affects the expression of FAS protein |
CTD |
PMID:17372815 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
EXP ISO |
[Atorvastatin co-treated with Acetylcysteine] inhibits the reaction [sodium arsenite results in increased expression of FASLG protein] Atorvastatin results in increased expression of FASLG protein modified form Atorvastatin inhibits the reaction [TNF protein results in decreased expression of and results in decreased secretion of FASLG protein modified form] |
CTD |
PMID:15063428 PMID:20946910 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
increases expression multiple interactions |
ISO EXP |
Atorvastatin results in increased expression of FASN mRNA [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of FASN protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of FASN protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of FASN mRNA] |
CTD |
PMID:11728391 PMID:12056585 PMID:32259528 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbxo32 |
F-box protein 32 |
increases expression |
EXP |
Atorvastatin results in increased expression of FBXO32 mRNA |
CTD |
PMID:27377005 |
|
NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of FGF15 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Foxo1 |
forkhead box O1 |
decreases phosphorylation |
ISO |
Atorvastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of FTH1 protein] |
CTD |
PMID:32976958 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gck |
glucokinase |
decreases expression multiple interactions |
ISO EXP |
Atorvastatin results in decreased expression of GCK protein NR1I2 protein promotes the reaction [Atorvastatin results in decreased expression of GCK protein] |
CTD |
PMID:26616219 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
EXP |
Atorvastatin promotes the reaction [dapagliflozin inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of GJA1 protein]] |
CTD |
PMID:34939712 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gng3 |
G protein subunit gamma 3 |
multiple interactions affects localization |
EXP |
[Isoproterenol co-treated with Atorvastatin] affects the localization of GNG3 protein Atorvastatin affects the localization of GNG3 protein |
CTD |
PMID:19136528 |
|
NCBI chr 1:205,731,837...205,733,603
Ensembl chr 1:205,731,837...205,733,603
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Streptozocin results in increased secretion of GOT1 protein] |
CTD |
PMID:30657622 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of GPAM mRNA] |
CTD |
PMID:19053045 |
|
NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO EXP |
[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the activity of GPT protein]; Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of GPT protein]; Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]; Buthionine Sulfoximine promotes the reaction [[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein] [Atorvastatin co-treated with triptolide] results in increased expression of GPT protein; [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of GPT protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of GPT protein]; Atorvastatin inhibits the reaction [Streptozocin results in increased secretion of GPT protein] |
CTD |
PMID:29679711 PMID:30657622 PMID:32259528 PMID:32976958 PMID:33600922 PMID:36006763 PMID:37023836 More...
|
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of GPX4 protein] |
CTD |
PMID:32976958 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
decreases expression |
ISO |
Atorvastatin results in decreased expression of HBEGF protein |
CTD |
PMID:18360054 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions affects binding increases expression increases activity |
ISO EXP |
Atorvastatin results in increased expression of and results in increased activity of HMGCR protein Atorvastatin binds to HMGCR protein Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of HMGCR mRNA]; Atorvastatin results in increased expression of and results in increased activity of HMGCR protein; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of HMGCR protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of HMGCR mRNA] |
CTD |
PMID:9512650 PMID:10357840 PMID:12056585 PMID:12065722 PMID:12612140 PMID:30273964 PMID:32048413 More...
|
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Atorvastatin results in increased expression of HMOX1 mRNA Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of HMOX1 protein] [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of HMOX1 protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of HMOX1 protein] |
CTD |
PMID:16410222 PMID:32259528 PMID:32976958 PMID:38484826 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA] |
CTD |
PMID:30273964 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Dietary Fats promotes the reaction [Isoproterenol results in increased expression of HTR7 mRNA]]; Atorvastatin inhibits the reaction [Isoproterenol promotes the reaction [Dietary Fats results in increased expression of HTR7 mRNA]] |
CTD |
PMID:32329363 |
|
NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
ISO EXP |
Atorvastatin inhibits the reaction [TNF results in increased expression of ICAM1] Atorvastatin results in increased expression of ICAM1 protein Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of ICAM1 protein]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of ICAM1 mRNA]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of ICAM1 protein] |
CTD |
PMID:12615677 PMID:17589825 PMID:19171469 PMID:25058445 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Sodium Glutamate results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:19800637 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il12a |
interleukin 12A |
decreases expression |
ISO |
Atorvastatin results in decreased expression of IL12A mRNA |
CTD |
PMID:12492458 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL18 protein] |
CTD |
PMID:37023836 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of IL1B mRNA]; Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of IL1B mRNA]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of IL1B protein] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL1B mRNA]; Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL1B protein] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of IL1B protein] |
CTD |
PMID:17589825 PMID:19482827 PMID:25058445 PMID:32048413 PMID:34939712 PMID:37023836 PMID:38213245 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
affects expression |
ISO |
Atorvastatin affects the expression of IL2RA protein |
CTD |
PMID:16387846 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression decreases secretion |
ISO EXP |
Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of IL6 mRNA]; Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of IL6 mRNA]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Atorvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Atorvastatin results in decreased expression of and results in decreased secretion of IL6 protein; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased expression of IL6 mRNA] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of IL6 mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of IL6 protein] Atorvastatin results in decreased expression of IL6 mRNA; Atorvastatin results in decreased expression of IL6 protein Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [Dietary Fats promotes the reaction [Isoproterenol results in increased expression of IL6 mRNA]]; Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [Isoproterenol promotes the reaction [Dietary Fats results in increased expression of IL6 mRNA]]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of IL6 protein] Atorvastatin results in decreased secretion of IL6 protein |
CTD |
PMID:12117737 PMID:16387846 PMID:17521631 PMID:19171469 PMID:19482827 PMID:19800637 PMID:25058445 PMID:25834641 PMID:32048413 PMID:32329363 PMID:37023836 PMID:38213245 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO EXP |
Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of INS1 protein] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of INS1 protein] |
CTD |
PMID:19800637 PMID:34939712 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of INS protein |
CTD |
PMID:19651449 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of IRAK1 mRNA; [Atorvastatin co-treated with Telmisartan] results in decreased expression of IRAK1 mRNA |
CTD |
PMID:20524934 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of IRF4 protein |
CTD |
PMID:33034787 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
ISO EXP |
Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]; geranylgeraniol inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]] |
CTD |
PMID:12500026 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itgal |
integrin subunit alpha L |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [TNF results in increased expression of ITGAL] |
CTD |
PMID:12615677 |
|
NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
|
|
G |
Itgam |
integrin subunit alpha M |
decreases expression |
ISO |
Atorvastatin results in decreased expression of ITGAM protein |
CTD |
PMID:18333374 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgax |
integrin subunit alpha X |
decreases expression |
ISO |
Atorvastatin results in decreased expression of ITGAX protein |
CTD |
PMID:18333374 |
|
NCBI chr 1:182,709,653...182,740,709
Ensembl chr 1:182,719,609...182,740,698
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions increases expression |
ISO EXP |
Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]; geranylgeraniol inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of ITGB1 mRNA] |
CTD |
PMID:12500026 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [TNF results in increased expression of ITGB2] |
CTD |
PMID:12615677 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Atorvastatin co-treated with Celecoxib] results in increased expression of JUN protein; Atorvastatin results in increased phosphorylation of and results in increased activity of JUN protein; Celecoxib promotes the reaction [Atorvastatin results in increased phosphorylation of and results in increased activity of JUN protein] |
CTD |
PMID:18172863 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity multiple interactions |
EXP |
Atorvastatin results in decreased activity of KCNH2 protein Berberine promotes the reaction [Atorvastatin results in decreased activity of KCNH2 protein] |
CTD |
PMID:30086269 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Khk |
ketohexokinase |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of KHK protein] |
CTD |
PMID:21122807 |
|
NCBI chr 6:25,445,298...25,455,834
Ensembl chr 6:25,445,300...25,455,717
|
|
G |
Kif6 |
kinesin family member 6 |
increases response to substance |
ISO |
KIF6 polymorphism results in increased susceptibility to Atorvastatin |
CTD |
PMID:21943003 |
|
NCBI chr 9:11,076,203...11,373,205
Ensembl chr 9:11,072,824...11,373,006
|
|
G |
Kpna2 |
karyopherin subunit alpha 2 |
affects localization multiple interactions |
ISO |
Atorvastatin affects the localization of KPNA2 protein [Ivermectin co-treated with Atorvastatin] affects the localization of KPNA2 protein |
CTD |
PMID:34696514 |
|
NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150
|
|
G |
Kpna7 |
karyopherin subunit alpha 7 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Poly I-C results in increased expression of KPNA7 mRNA] |
CTD |
PMID:34696514 |
|
NCBI chr12:9,576,378...9,635,247
Ensembl chr12:9,576,378...9,612,833
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein] |
CTD |
PMID:30273964 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
ISO EXP |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of LCN2 mRNA [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of LCN2 protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of LCN2 protein] |
CTD |
PMID:29679711 PMID:32259528 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases activity multiple interactions increases expression |
ISO EXP |
Atorvastatin results in increased activity of LDLR protein Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Atorvastatin inhibits the reaction [Dietary Fats results in decreased expression of LDLR mRNA] Atorvastatin results in increased expression of LDLR mRNA |
CTD |
PMID:10357840 PMID:11728391 PMID:12612140 PMID:24502637 PMID:30273964 PMID:32048413 More...
|
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
Atorvastatin affects the reaction [Fructose results in increased expression of LEP protein] |
CTD |
PMID:21122807 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein] |
CTD |
PMID:30273964 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:34939712 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation decreases phosphorylation |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK1 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK1 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK1 protein] Atorvastatin inhibits the reaction [AGT protein results in increased activity of MAPK1 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Atorvastatin results in increased phosphorylation of MAPK1 protein] Atorvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:16470222 PMID:18339080 PMID:18360054 PMID:19451411 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO EXP |
Atorvastatin inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK14 protein] Atorvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:17589825 PMID:19767766 PMID:20018284 PMID:20305681 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK3 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK3 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK3 protein] Atorvastatin inhibits the reaction [AGT protein results in increased activity of MAPK3 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Atorvastatin results in increased phosphorylation of MAPK3 protein] Atorvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:16470222 PMID:18339080 PMID:18360054 PMID:19451411 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mb |
myoglobin |
increases expression multiple interactions |
EXP ISO |
Atorvastatin results in increased expression of MB protein [Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased secretion of MB protein |
CTD |
PMID:27815113 PMID:29679711 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
Atorvastatin results in decreased expression of MCL1 protein |
CTD |
PMID:16470222 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
Atorvastatin results in increased expression of MDM2 protein |
CTD |
PMID:29630879 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mef2d |
myocyte enhancer factor 2D |
increases expression |
EXP |
Atorvastatin results in increased expression of MEF2D mRNA |
CTD |
PMID:27377005 |
|
NCBI chr 2:173,606,054...173,635,620
Ensembl chr 2:173,606,490...173,634,457
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of MFN2 protein] |
CTD |
PMID:24721408 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mir133b |
microRNA 133b |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR133B mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 9:23,098,134...23,098,217
Ensembl chr 9:23,098,134...23,098,217
|
|
G |
Mir145 |
microRNA 145 |
increases expression |
ISO |
Atorvastatin results in increased expression of MIR145 mRNA |
CTD |
PMID:29630879 |
|
NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727
|
|
G |
Mir146a |
microRNA 146a |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of MIR146A; [Atorvastatin co-treated with Telmisartan] results in decreased expression of MIR146A |
CTD |
PMID:20524934 |
|
NCBI chr10:27,848,516...27,848,610
Ensembl chr10:27,848,516...27,848,610
|
|
G |
Mir146b |
microRNA 146b |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of MIR146B; [Atorvastatin co-treated with Telmisartan] results in decreased expression of MIR146B |
CTD |
PMID:20524934 |
|
NCBI chr 1:245,203,438...245,203,525
Ensembl chr 1:245,203,438...245,203,525
|
|
G |
Mir206 |
microRNA 206 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR206 mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 9:23,094,249...23,094,332
Ensembl chr 9:23,094,249...23,094,332
|
|
G |
Mir221 |
microRNA 221 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of MIR221 |
CTD |
PMID:25517390 |
|
NCBI chr X:3,429,465...3,429,573
Ensembl chr X:3,429,465...3,429,573
|
|
G |
Mir222 |
microRNA 222 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of MIR222 |
CTD |
PMID:25517390 |
|
NCBI chr X:3,428,904...3,429,006
Ensembl chr X:3,428,904...3,429,006
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose affects the localization of and results in increased activity of MLXIPL protein]; Atorvastatin inhibits the reaction [Fructose results in increased expression of MLXIPL protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin inhibits the reaction [Fructose results in increased activity of MLXIPL protein]] |
CTD |
PMID:19053045 PMID:21122807 |
|
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression increases activity |
ISO EXP |
Atorvastatin results in decreased expression of MMP2 protein Atorvastatin results in increased activity of MMP2 protein |
CTD |
PMID:18360054 PMID:23831763 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases activity |
ISO EXP |
Atorvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]; Atorvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]; Sildenafil Citrate promotes the reaction [Atorvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]] Atorvastatin results in increased activity of MMP9 protein |
CTD |
PMID:15728660 PMID:23831763 PMID:26614570 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Paraquat results in increased activity of MPO protein] |
CTD |
PMID:27883937 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
multiple interactions |
ISO |
[Rosiglitazone co-treated with Atorvastatin] results in increased expression of MSR1 mRNA |
CTD |
PMID:15183127 |
|
NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676
|
|
G |
Mstn |
myostatin |
increases expression |
ISO |
Atorvastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
affects expression multiple interactions |
EXP |
Atorvastatin affects the expression of COX1 mRNA Quercetin inhibits the reaction [Atorvastatin affects the expression of COX1 mRNA] |
CTD |
PMID:21775390 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt1-ps2 |
metallothionein 1, pseudogene 2 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of MT1-PS2 mRNA] |
CTD |
PMID:21122807 |
|
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of MT2A mRNA] |
CTD |
PMID:21122807 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of and results in increased phosphorylation of MTOR protein] |
CTD |
PMID:34939712 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression multiple interactions decreases expression |
EXP ISO |
Atorvastatin results in increased expression of MTTP mRNA Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of MTTP mRNA] Atorvastatin results in decreased expression of MTTP mRNA |
CTD |
PMID:10357840 PMID:12056585 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Atorvastatin results in decreased expression of MYC mRNA |
CTD |
PMID:29630879 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of MYD88 mRNA]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of MYD88 protein] |
CTD |
PMID:38213245 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Myh2 |
myosin heavy chain 2 |
multiple interactions affects expression |
ISO |
[PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of MYH2 protein Atorvastatin affects the expression of MYH2 protein |
CTD |
PMID:30511338 |
|
NCBI chr10:51,856,738...51,883,236
Ensembl chr10:51,856,738...51,883,236
|
|
G |
Nfe2l1 |
NFE2 like bZIP transcription factor 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of NFE2L1 mRNA |
CTD |
PMID:30511338 |
|
NCBI chr10:81,796,055...81,812,926
Ensembl chr10:81,800,366...81,832,318
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression decreases expression |
ISO EXP |
[PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of NFE2L2 mRNA; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of NFE2L2 protein] Atorvastatin results in increased expression of NFE2L2 mRNA Atorvastatin results in decreased expression of NFE2L2 protein 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in decreased expression of NFE2L2 protein]; Atorvastatin results in increased expression of and affects the localization of and results in increased activity of NFE2L2 protein [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of NFE2L2 protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of NFE2L2 protein] |
CTD |
PMID:30511338 PMID:31423616 PMID:32259528 PMID:32976958 PMID:38484826 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[Ivermectin co-treated with Atorvastatin] inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA]; Atorvastatin inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of NFKB1 mRNA] |
CTD |
PMID:34696514 PMID:37023836 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of NLRP3 protein] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of NLRP3 mRNA] |
CTD |
PMID:34939712 PMID:37023836 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nnmt |
nicotinamide N-methyltransferase |
increases expression |
ISO |
Atorvastatin results in increased expression of NNMT protein |
CTD |
PMID:33073877 |
|
NCBI chr 8:48,928,663...48,947,734
Ensembl chr 8:48,933,598...48,946,655
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
EXP |
Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of NOS2 mRNA]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of NOS2 protein] Atorvastatin results in decreased expression of NOS2 mRNA; Atorvastatin results in decreased expression of NOS2 protein |
CTD |
PMID:15166393 PMID:25058445 PMID:25218292 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases expression affects response to substance |
ISO EXP |
Atorvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NOS3 mRNA]; Atorvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NOS3 protein]; Melatonin promotes the reaction [Atorvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NOS3 protein]] Atorvastatin results in increased expression of NOS3 mRNA; Atorvastatin results in increased expression of NOS3 protein [Dexamethasone co-treated with Atorvastatin] results in increased expression of NOS3 mRNA; [Losartan co-treated with Atorvastatin] results in increased expression of NOS3 mRNA; Atorvastatin inhibits the reaction [Dexamethasone results in decreased expression of NOS3 mRNA]; Atorvastatin inhibits the reaction [sodium arsenite results in decreased expression of and results in decreased phosphorylation of NOS3 protein]; Atorvastatin inhibits the reaction [sodium arsenite results in decreased expression of NOS3 mRNA]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of NOS3 protein]; Atorvastatin inhibits the reaction [Streptozocin results in decreased expression of NOS3 protein] Atorvastatin inhibits the reaction [Homocysteine results in decreased expression of NOS3 mRNA]; Atorvastatin inhibits the reaction [Homocysteine results in decreased phosphorylation of NOS3 protein] NOS3 promoter SNP affects the susceptibility to Atorvastatin |
CTD |
PMID:12490971 PMID:15166393 PMID:16410222 PMID:16962929 PMID:17042910 PMID:17589825 PMID:20305681 PMID:21585521 PMID:23091284 PMID:25058445 PMID:25218292 PMID:25517390 More...
|
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [AGT protein results in increased expression of NOX1 protein] |
CTD |
PMID:19451411 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
EXP ISO |
Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of NOX4 mRNA] Atorvastatin inhibits the reaction [Homocysteine results in increased expression of NOX4 mRNA] |
CTD |
PMID:20018284 PMID:25218292 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA] |
CTD |
PMID:19136528 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression |
ISO |
Atorvastatin results in decreased expression of NPPB protein |
CTD |
PMID:18360054 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of NR0B2 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases expression |
ISO EXP |
[Atorvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Atorvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; NR1I2 protein promotes the reaction [Atorvastatin results in decreased expression of GCK protein]; NR1I2 protein promotes the reaction [Atorvastatin results in decreased expression of SLC2A2 protein] Atorvastatin promotes the reaction [Dietary Fats results in increased expression of NR1I2 protein] Atorvastatin binds to and results in increased activity of NR1I2 protein Atorvastatin results in increased expression of NR1I2 protein |
CTD |
PMID:15986414 PMID:24204015 PMID:26616219 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO EXP |
Atorvastatin results in increased activity of NR1I3 protein |
CTD |
PMID:15802384 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions affects expression increases expression |
EXP |
Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of NRF1 mRNA]; Quercetin inhibits the reaction [Atorvastatin affects the expression of NRF1 mRNA] |
CTD |
PMID:21775390 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; [Atorvastatin co-treated with Celecoxib] results in increased cleavage of PARP1 protein; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; CDKN1A protein mutant form inhibits the reaction [Atorvastatin results in increased cleavage of PARP1 protein] ATG5 mutant form promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein] |
CTD |
PMID:16470222 PMID:18172863 PMID:20876807 PMID:31423616 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcyt1a |
phosphate cytidylyltransferase 1A, choline |
increases activity |
EXP |
Atorvastatin results in increased activity of PCYT1A protein |
CTD |
PMID:12056585 |
|
NCBI chr11:68,313,860...68,357,828
Ensembl chr11:68,313,882...68,357,357
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PDK4 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PDK4 protein]] |
CTD |
PMID:22343369 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase-1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Celecoxib] results in decreased phosphorylation of and results in decreased expression of PDPK1 protein |
CTD |
PMID:18172863 |
|
NCBI chr10:13,105,435...13,182,664
Ensembl chr10:13,105,498...13,174,623
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
decreases expression |
ISO |
Atorvastatin results in decreased expression of PIK3CA mRNA |
CTD |
PMID:29630879 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pklr |
pyruvate kinase L/R |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of PKLR mRNA] |
CTD |
PMID:19053045 PMID:21122807 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases expression |
EXP |
Atorvastatin results in increased expression of PKM mRNA |
CTD |
PMID:27377005 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases expression |
ISO |
Atorvastatin results in decreased expression of PLAU protein |
CTD |
PMID:16410222 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plin2 |
perilipin 2 |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of PLIN2 protein] |
CTD |
PMID:34939712 |
|
NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Pomc |
proopiomelanocortin |
increases expression |
EXP |
Atorvastatin results in increased expression of POMC protein |
CTD |
PMID:29574565 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Pon1 |
paraoxonase 1 |
increases activity multiple interactions increases expression |
ISO EXP |
Atorvastatin results in increased activity of PON1 protein Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein] PON1 gene polymorphism affects the reaction [Atorvastatin results in increased abundance of Cholesterol, HDL]; PON1 gene SNP affects the reaction [Atorvastatin results in increased abundance of Cholesterol, HDL]; PON1 protein affects the reaction [Atorvastatin results in increased abundance of Cholesterol, HDL] Atorvastatin results in increased expression of PON1 mRNA |
CTD |
PMID:15324535 PMID:15690306 PMID:15969877 PMID:16238680 PMID:30273964 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Pon2 |
paraoxonase 2 |
increases activity increases expression |
ISO |
Atorvastatin results in increased activity of PON2 protein Atorvastatin results in increased expression of PON2 mRNA |
CTD |
PMID:14592851 |
|
NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression multiple interactions |
ISO EXP |
Atorvastatin results in decreased expression of PPARA mRNA Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of PPARA protein]; Atorvastatin inhibits the reaction [Fructose results in increased expression of PPARA protein] |
CTD |
PMID:12065722 PMID:18812576 PMID:21554872 PMID:32259528 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of PPARG mRNA] |
CTD |
PMID:36006763 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression affects expression multiple interactions increases expression |
EXP ISO |
Atorvastatin results in decreased expression of PPARGC1A mRNA Atorvastatin affects the expression of PPARGC1A mRNA Atorvastatin results in decreased expression of PPARGC1A protein [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of PPARGC1A mRNA Atorvastatin results in increased expression of PPARGC1A mRNA [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of PPARGC1A protein]; Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of PPARGC1A mRNA]; Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PPARGC1A protein]; Farnesol inhibits the reaction [Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PPARGC1A protein]] |
CTD |
PMID:21775390 PMID:22343369 PMID:30511338 PMID:32259528 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
affects expression decreases expression affects response to substance multiple interactions |
EXP ISO |
Atorvastatin affects the expression of PPARGC1B mRNA Atorvastatin results in decreased expression of PPARGC1B mRNA PPARGC1B protein affects the susceptibility to Atorvastatin Atorvastatin affects the expression of PPARGC1B protein [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the cleavage of CASP3 protein; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of MYH2 protein; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of NFE2L2 mRNA; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of PPARGC1A mRNA; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of PPARGC1B mRNA; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of SOD2 protein; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of TFAM mRNA; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of TOMM20 protein Quercetin inhibits the reaction [Atorvastatin affects the expression of PPARGC1B mRNA] |
CTD |
PMID:21775390 PMID:30511338 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
increases expression |
EXP |
Atorvastatin results in increased expression of PPP3CA mRNA |
CTD |
PMID:27377005 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases activity |
ISO |
Atorvastatin results in increased activity of PRKAA1 protein |
CTD |
PMID:33073877 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
Atorvastatin results in increased phosphorylation of and results in increased activity of PRKACA protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin results in increased phosphorylation of and results in increased activity of PRKACA protein] |
CTD |
PMID:19053045 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
EXP |
[Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of and results in increased phosphorylation of PRKCA protein] |
CTD |
PMID:32259528 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcq |
protein kinase C, theta |
increases expression |
EXP |
Atorvastatin results in increased expression of PRKCQ mRNA; Atorvastatin results in increased expression of PRKCQ protein |
CTD |
PMID:27377005 |
|
NCBI chr17:67,246,394...67,379,049
Ensembl chr17:67,246,394...67,378,704
|
|
G |
Prkcz |
protein kinase C, zeta |
multiple interactions |
EXP |
[Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of PRKCZ protein] |
CTD |
PMID:32259528 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
EXP |
Atorvastatin results in increased expression of PTEN protein |
CTD |
PMID:15837263 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP |
[Atorvastatin co-treated with Pioglitazone] results in increased expression of PTGS2 protein; [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of PTGS2 protein] Atorvastatin results in increased expression of PTGS2 protein |
CTD |
PMID:16908763 PMID:34939712 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
ISO EXP |
[Poly I-C co-treated with Atorvastatin] results in decreased expression of RAC1 mRNA; Atorvastatin inhibits the reaction [Glucose results in increased localization of RAC1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin inhibits the reaction [Glucose results in increased localization of RAC1 protein]] Atorvastatin inhibits the reaction [Streptozocin results in increased activity of RAC1 protein] Atorvastatin inhibits the reaction [Streptozocin results in increased activity of and results in increased localization of RAC1 protein] |
CTD |
PMID:17279352 PMID:17589825 PMID:34696514 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Celecoxib] results in decreased expression of RB1 protein modified form; [Atorvastatin co-treated with Celecoxib] results in increased expression of RB1 protein |
CTD |
PMID:18172863 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of RELA protein]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of RELA mRNA]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of RELA protein]; Atorvastatin inhibits the reaction [Nitroglycerin results in increased localization of RELA protein] Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of RELA protein] |
CTD |
PMID:19733216 PMID:34939712 PMID:37121058 PMID:38213245 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhoa |
ras homolog family member A |
increases expression decreases activity multiple interactions decreases localization |
ISO EXP |
Atorvastatin results in increased expression of RHOA protein Atorvastatin results in decreased activity of RHOA protein Atorvastatin inhibits the reaction [Streptozocin results in increased activity of RHOA protein] [Poly I-C co-treated with Atorvastatin co-treated with Ivermectin] results in increased expression of RHOA mRNA; [Poly I-C co-treated with Atorvastatin] results in increased expression of RHOA mRNA; Atorvastatin results in increased localization of and results in decreased prenylation of RHOA protein; Celecoxib promotes the reaction [Atorvastatin results in decreased localization of RHOA protein]; Celecoxib promotes the reaction [Atorvastatin results in increased expression of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in decreased activity of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in increased localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased activity of RHOA protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased localization of RHOA protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased expression of BCL2 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK1 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK3 protein]; RHOA protein inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein] |
CTD |
PMID:16470222 PMID:17589825 PMID:18172863 PMID:34696514 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rhob |
ras homolog family member B |
increases localization increases expression multiple interactions |
ISO |
Atorvastatin results in increased localization of RHOB protein Atorvastatin results in increased expression of RHOB protein [Atorvastatin co-treated with Celecoxib] results in increased localization of RHOB protein; Celecoxib promotes the reaction [Atorvastatin results in increased expression of RHOB protein] |
CTD |
PMID:18172863 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rhoc |
ras homolog family member C |
decreases localization multiple interactions increases expression |
ISO |
Atorvastatin results in decreased localization of RHOC protein Celecoxib promotes the reaction [Atorvastatin results in decreased localization of RHOC protein]; Celecoxib promotes the reaction [Atorvastatin results in increased expression of RHOC protein] |
CTD |
PMID:18172863 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rpl36a |
ribosomal protein L36A |
increases expression |
EXP |
Atorvastatin results in increased expression of CYP21A2 mRNA |
CTD |
PMID:29574565 |
|
NCBI chr X:97,766,179...97,768,892
Ensembl chr X:97,766,179...97,768,892 Ensembl chr20:97,766,179...97,768,892
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
ISO |
[Rosiglitazone co-treated with Atorvastatin] results in increased expression of SCARB1 protein |
CTD |
PMID:15183127 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of SCD1 mRNA] |
CTD |
PMID:21122807 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sele |
selectin E |
increases expression |
ISO |
Atorvastatin results in increased expression of SELE protein |
CTD |
PMID:19171469 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:21122807 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sgk2 |
serum/glucocorticoid regulated kinase 2 |
multiple interactions |
ISO |
[Atorvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr 3:151,644,102...151,669,480
Ensembl chr 3:151,644,102...151,669,480
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions increases phosphorylation |
EXP ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SIRT1 protein] Atorvastatin results in increased phosphorylation of SIRT1 protein |
CTD |
PMID:33073877 PMID:34939712 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of SLC10A1 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of SLC10A2 mRNA; Atorvastatin results in increased expression of SLC10A2 protein |
CTD |
PMID:15986414 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [APP protein results in decreased expression of SLC1A2 protein] |
CTD |
PMID:20816828 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc1a3 |
solute carrier family 1 member 3 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [APP protein results in decreased expression of SLC1A3 protein] |
CTD |
PMID:20816828 |
|
NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions increases expression |
ISO |
Atorvastatin inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] Atorvastatin results in increased expression of SLC22A1 mRNA |
CTD |
PMID:21641380 PMID:25278499 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] |
CTD |
PMID:21641380 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of SLC29A1 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
decreases expression multiple interactions |
EXP ISO |
Atorvastatin results in decreased expression of SLC2A2 protein NR1I2 protein promotes the reaction [Atorvastatin results in decreased expression of SLC2A2 protein] |
CTD |
PMID:26616219 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Sodium Glutamate results in decreased expression of SLC2A4 mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in decreased expression of SLC2A4 protein]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of SLC2A4 mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of SLC2A4 protein] |
CTD |
PMID:19800637 PMID:25834641 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc4a1 |
solute carrier family 4 member 1 (Diego blood group) |
multiple interactions |
EXP |
[Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite affects the localization of SLC4A1 protein] |
CTD |
PMID:20946910 |
|
NCBI chr10:87,306,865...87,323,132
Ensembl chr10:87,306,872...87,323,117
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Monocrotaline results in increased expression of SLC6A4 protein] |
CTD |
PMID:17575010 |
|
NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression decreases expression |
ISO EXP |
Atorvastatin results in increased expression of SLCO1A4 mRNA; Atorvastatin results in increased expression of SLCO1A4 protein Atorvastatin results in decreased expression of SLCO1A4 protein |
CTD |
PMID:15986414 PMID:24909372 PMID:25278499 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
increases expression increases uptake multiple interactions |
ISO |
Atorvastatin results in increased expression of SLCO1B2 mRNA SLCO1B3 protein results in increased uptake of Atorvastatin glimepiride affects the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Glyburide inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Nateglinide inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; repaglinide inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Rosiglitazone inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Sulfobromophthalein inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin] |
CTD |
PMID:23121773 PMID:25106415 PMID:25278499 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
increases uptake multiple interactions |
ISO |
SLCO2B1 protein results in increased uptake of Atorvastatin glimepiride inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Glyburide inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Nateglinide inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; repaglinide inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Rosiglitazone inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Sulfobromophthalein inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin] |
CTD |
PMID:23121773 PMID:25106415 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [AGT protein results in decreased expression of SOD1 protein] |
CTD |
PMID:19451411 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions affects expression decreases expression increases expression |
EXP ISO |
Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of SOD2 mRNA]; Quercetin affects the reaction [Atorvastatin affects the expression of SOD2 mRNA] 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin affects the expression of SOD2 protein] [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of SOD2 protein Atorvastatin results in decreased expression of SOD2 protein |
CTD |
PMID:21775390 PMID:30511338 PMID:31423616 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sod3 |
superoxide dismutase 3 |
increases expression |
EXP |
Atorvastatin results in increased expression of SOD3 protein |
CTD |
PMID:19451411 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of SQSTM1 protein] |
CTD |
PMID:34939712 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
[Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of SREBF1 protein]; Atorvastatin inhibits the reaction [Fructose results in increased activity of SREBF1 protein] |
CTD |
PMID:19053045 PMID:32259528 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions increases expression increases localization |
EXP ISO |
Atorvastatin results in increased activity of and results in increased localization of SREBF2 protein; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of SREBF2 mRNA] Atorvastatin results in increased localization of SREBF2 protein |
CTD |
PMID:11728391 PMID:12056585 PMID:12065722 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Star |
steroidogenic acute regulatory protein |
affects expression |
EXP |
Atorvastatin affects the expression of STAR mRNA |
CTD |
PMID:29574565 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Syp |
synaptophysin |
increases expression |
EXP |
Atorvastatin results in increased expression of SYP protein |
CTD |
PMID:15255259 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression decreases expression multiple interactions |
EXP ISO |
Atorvastatin results in increased expression of TFAM mRNA Atorvastatin results in decreased expression of TFAM protein [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of TFAM mRNA Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of TFAM mRNA] |
CTD |
PMID:21775390 PMID:30511338 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tfrc |
transferrin receptor |
affects expression multiple interactions |
ISO |
Atorvastatin affects the expression of TFRC protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TFRC protein] |
CTD |
PMID:16387846 PMID:32976958 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [Atorvastatin inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA]]; Atorvastatin inhibits the reaction [Dietary Fats promotes the reaction [Isoproterenol results in increased expression of TGFB1 mRNA]]; Atorvastatin inhibits the reaction [Isoproterenol promotes the reaction [Dietary Fats results in increased expression of TGFB1 mRNA]]; Atorvastatin inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA] |
CTD |
PMID:24161914 PMID:32329363 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thbs1 |
thrombospondin 1 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of THBS1 mRNA |
CTD |
PMID:16410222 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of TLR2 protein |
CTD |
PMID:16387846 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions decreases expression increases expression |
ISO EXP |
[Atorvastatin co-treated with Enalapril] results in decreased expression of TLR4 mRNA; [Atorvastatin co-treated with Enalapril] results in decreased expression of TLR4 protein; [Atorvastatin co-treated with Telmisartan] results in decreased expression of TLR4 mRNA; [Atorvastatin co-treated with Telmisartan] results in decreased expression of TLR4 protein Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of TLR4 mRNA]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of TLR4 protein]; Atorvastatin inhibits the reaction [Paraquat results in increased expression of TLR4 mRNA]; Atorvastatin inhibits the reaction [Paraquat results in increased expression of TLR4 protein] Atorvastatin results in decreased expression of TLR4 mRNA; Atorvastatin results in decreased expression of TLR4 protein Atorvastatin results in increased expression of TLR4 protein |
CTD |
PMID:16387846 PMID:20524934 PMID:27883937 PMID:38213245 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression decreases secretion |
ISO EXP |
Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [TNF protein results in decreased expression of and results in decreased secretion of FASLG protein modified form]; Atorvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Atorvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Atorvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Atorvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Atorvastatin inhibits the reaction [TNF results in increased expression of ITGAL]; Atorvastatin inhibits the reaction [TNF results in increased expression of ITGB2]; Atorvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of TNF protein] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [Dietary Fats promotes the reaction [Isoproterenol results in increased expression of TNF mRNA]]; Atorvastatin inhibits the reaction [Isoproterenol promotes the reaction [Dietary Fats results in increased expression of TNF mRNA]]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PDK4 protein]; Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PPARGC1A protein]; Atorvastatin inhibits the reaction [TNF protein results in increased oxidation of Glucose]; Farnesol inhibits the reaction [Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PPARGC1A protein]]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PDK4 protein]] Atorvastatin results in decreased expression of TNF mRNA Atorvastatin results in decreased secretion of TNF protein Atorvastatin results in decreased expression of TNF protein |
CTD |
PMID:12117737 PMID:12615677 PMID:15063428 PMID:16387846 PMID:17521631 PMID:17589825 PMID:19171469 PMID:19482827 PMID:19800637 PMID:22343369 PMID:29630879 PMID:32329363 PMID:34939712 PMID:36006763 PMID:37023836 PMID:38213245 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
decreases expression |
ISO |
Atorvastatin results in decreased expression of TNFRSF1A protein |
CTD |
PMID:16360360 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases response to substance |
ISO |
TNFSF10 protein results in increased susceptibility to Atorvastatin |
CTD |
PMID:21910007 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
multiple interactions increases expression |
ISO |
[PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of TOMM20 protein Atorvastatin results in increased expression of TOMM20 protein |
CTD |
PMID:30511338 |
|
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO |
Atorvastatin results in increased expression of TP53 protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TRP53 protein] |
CTD |
PMID:29630879 PMID:37121058 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of TRAF6 mRNA; [Atorvastatin co-treated with Telmisartan] results in decreased expression of TRAF6 mRNA |
CTD |
PMID:20524934 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
increases expression |
EXP |
Atorvastatin results in increased expression of TUBB3 protein |
CTD |
PMID:15255259 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
decreases expression multiple interactions |
ISO EXP |
Atorvastatin results in decreased expression of VCAM1 mRNA; Atorvastatin results in decreased expression of VCAM1 protein Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of VCAM1 protein]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of VCAM1 mRNA]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of VCAM1 protein] |
CTD |
PMID:17589825 PMID:17673219 PMID:22245985 PMID:25058445 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfd |
vascular endothelial growth factor D |
affects expression |
ISO |
Atorvastatin affects the expression of VEGFD mRNA |
CTD |
PMID:16410222 |
|
NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of VIM protein] |
CTD |
PMID:34939712 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vwf |
von Willebrand factor |
increases expression |
ISO |
Atorvastatin results in increased expression of VWF protein |
CTD |
PMID:19171469 |
|
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of WT1 protein] |
CTD |
PMID:34939712 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|
G |
Xirp1 |
xin actin-binding repeat containing 1 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of XIRP1 mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 8:119,744,778...119,757,547
Ensembl chr 8:119,747,419...119,757,349
|
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
multiple interactions increases expression |
ISO |
[sodium bisulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in increased expression of ACSL4 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of ACSL4 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in increased expression of ACSL4 mRNA] |
CTD |
PMID:36843388 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression |
ISO |
beryllium sulfate results in increased expression of ACTA2 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Amot |
angiomotin |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of AMOT mRNA |
CTD |
PMID:35679967 |
|
NCBI chr X:108,982,399...109,041,265
Ensembl chr X:108,984,022...109,041,272
|
|
G |
Anxa5 |
annexin A5 |
increases expression |
ISO |
beryllium sulfate results in increased expression of ANXA5 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Arhgap26 |
Rho GTPase activating protein 26 |
increases expression decreases expression |
ISO |
beryllium sulfate results in increased expression of ARHGAP26 mRNA beryllium sulfate results in decreased expression of ARHGAP26 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr18:30,835,806...31,237,945
Ensembl chr18:30,838,671...31,235,194
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions increases secretion |
ISO |
beryllium sulfate promotes the reaction [RUNX1 protein binds to CCL3 promoter] beryllium sulfate results in increased secretion of CCL3 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases secretion |
ISO |
beryllium sulfate results in increased secretion of CCL4 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
beryllium sulfate results in increased expression of CCL5 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnt1 |
cyclin T1 |
increases expression |
ISO |
beryllium sulfate results in increased expression of CCNT1 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr 7:129,687,146...129,718,080
Ensembl chr 7:129,691,209...129,717,871
|
|
G |
Cd44 |
CD44 molecule |
increases expression |
ISO |
beryllium sulfate results in increased expression of CD44 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
beryllium sulfate results in increased expression of CD86 protein |
CTD |
PMID:19665512 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
beryllium sulfate promotes the reaction [TP53 protein binds to CDKN1A promoter] beryllium sulfate results in increased expression of CDKN1A mRNA; beryllium sulfate results in increased expression of CDKN1A protein |
CTD |
PMID:17395767 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
ISO |
beryllium sulfate results in increased expression of CDKN2A mRNA; beryllium sulfate results in increased expression of CDKN2A protein |
CTD |
PMID:17395767 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
[beryllium sulfate co-treated with IFNG protein] results in increased expression of CREB1 protein |
CTD |
PMID:10755711 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cryaa |
crystallin, alpha A |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of CRYAA mRNA |
CTD |
PMID:35679967 |
|
NCBI chr20:9,783,605...9,787,351
Ensembl chr20:9,783,605...9,787,349
|
|
G |
Ctsl |
cathepsin L |
increases expression |
ISO |
beryllium sulfate results in increased expression of CTSL mRNA |
CTD |
PMID:16314022 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cul9 |
cullin 9 |
increases expression decreases expression |
ISO |
beryllium sulfate results in increased expression of CUL9 mRNA beryllium sulfate results in decreased expression of CUL9 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr 9:14,435,948...14,479,552
Ensembl chr 9:14,436,111...14,479,548
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases secretion |
ISO |
beryllium sulfate results in increased secretion of CXCL1 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases secretion |
ISO |
beryllium sulfate results in increased secretion of CXCL1 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Ddhd2 |
DDHD domain containing 2 |
increases expression |
ISO |
beryllium sulfate results in increased expression of DDHD2 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr16:66,319,469...66,349,025
Ensembl chr16:66,319,466...66,349,023
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
beryllium sulfate results in increased expression of EGR2 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
beryllium sulfate results in increased expression of FOS mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [beryllium sulfate results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [beryllium sulfate results in increased expression of FOS mRNA]; Ro 31-8220 inhibits the reaction [beryllium sulfate results in increased expression of FOS mRNA] |
CTD |
PMID:11568973 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions decreases expression |
ISO |
[sodium sulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 mRNA]; [sodium sulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 protein]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 protein]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of FTH1 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of FTH1 protein] beryllium sulfate results in decreased expression of FTH1 mRNA; beryllium sulfate results in decreased expression of FTH1 protein |
CTD |
PMID:36843388 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions decreases expression |
ISO |
[sodium bisulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in decreased expression of GPX4 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of GPX4 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of GPX4 mRNA] |
CTD |
PMID:36843388 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
increases expression |
ISO |
beryllium sulfate results in increased expression of HNRNPA1 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases secretion increases expression |
ISO |
3,3',4,5'-tetrahydroxystilbene inhibits the reaction [beryllium sulfate results in increased expression of ICAM1 mRNA]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [beryllium sulfate results in increased secretion of ICAM1 protein]; Dimethyl Sulfoxide inhibits the reaction [beryllium sulfate results in increased secretion of ICAM1 protein] beryllium sulfate results in increased expression of ICAM1 mRNA; beryllium sulfate results in increased expression of ICAM1 protein |
CTD |
PMID:18539414 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
increases expression multiple interactions |
ISO |
beryllium sulfate results in increased expression of IFNG protein [beryllium sulfate co-treated with IFNG protein] results in increased expression of CREB1 protein; [beryllium sulfate co-treated with IFNG protein] results in increased expression of JUN protein; [beryllium sulfate co-treated with IFNG protein] results in increased expression of JUNB protein; [beryllium sulfate co-treated with IFNG protein] results in increased expression of NFKB1 protein; beryllium sulfate promotes the reaction [IFNG protein results in increased expression of TNF protein] |
CTD |
PMID:10755710 PMID:10755711 PMID:20974702 PMID:33197057 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL10 protein |
CTD |
PMID:33197057 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL18 mRNA; beryllium sulfate results in increased expression of IL18 protein |
CTD |
PMID:16100009 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL2 mRNA |
CTD |
PMID:9328138 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il5 |
interleukin 5 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL5 mRNA |
CTD |
PMID:9328138 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL6 mRNA |
CTD |
PMID:9328138 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb3 |
integrin subunit beta 3 |
increases expression |
ISO |
beryllium sulfate results in increased expression of ITGB3 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [beryllium sulfate results in increased expression of JUN mRNA]; [beryllium sulfate co-treated with IFNG protein] results in increased expression of JUN protein; Dactinomycin inhibits the reaction [beryllium sulfate results in increased expression of JUN mRNA]; Ro 31-8220 inhibits the reaction [beryllium sulfate results in increased expression of JUN mRNA] |
CTD |
PMID:10755711 PMID:11568973 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[beryllium sulfate co-treated with IFNG protein] results in increased expression of JUNB protein |
CTD |
PMID:10755711 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Krt4 |
keratin 4 |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of KRT4 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr 7:133,046,067...133,052,027
Ensembl chr 7:133,046,515...133,052,019
|
|
G |
Mfsd14b |
major facilitator superfamily domain containing 14B |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of MFSD14B mRNA |
CTD |
PMID:35679967 |
|
NCBI chr17:77,895...130,837
Ensembl chr17:77,840...130,839
|
|
G |
Mir1306 |
microRNA 1306 |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR1306 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr11:82,709,651...82,709,723
Ensembl chr11:82,709,637...82,709,719
|
|
G |
Mir150 |
microRNA 150 |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR150 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr 1:95,605,024...95,605,108
Ensembl chr 1:95,605,024...95,605,108
|
|
G |
Mir193b |
microRNA 193b |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR193B mRNA |
CTD |
PMID:33197057 |
|
NCBI chr10:1,317,742...1,317,824
Ensembl chr10:1,317,742...1,317,824
|
|
G |
Mir23b |
microRNA 23b |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of MIR23B mRNA |
CTD |
PMID:33197057 |
|
NCBI chr17:1,813,667...1,813,763
Ensembl chr17:1,813,667...1,813,763
|
|
G |
Mir324 |
microRNA 324 |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR324 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr10:54,734,680...54,734,762
Ensembl chr10:54,734,678...54,734,766
|
|
G |
Mir363 |
microRNA 363 |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR363 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr X:132,421,791...132,421,877
Ensembl chr X:132,421,791...132,421,877
|
|
G |
Mir484 |
microRNA 484 |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of MIR484 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr10:887,684...887,760
Ensembl chr10:887,684...887,760
|
|
G |
Mir504 |
microRNA 504 |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR504 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr X:137,318,540...137,318,616
Ensembl chr X:137,318,540...137,318,616
|
|
G |
Mir877 |
microRNA 877 |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR877 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr20:2,811,476...2,811,560
Ensembl chr20:2,811,476...2,811,560
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
EXP |
beryllium sulfate results in increased expression of MYC protein |
CTD |
PMID:2009323 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ncoa4 |
nuclear receptor coactivator 4 |
multiple interactions increases expression |
ISO |
[sodium sulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 mRNA]; [sodium sulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 protein]; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 protein]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of FTH1 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of FTH1 protein]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of GPX4 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of SLC7A11 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in increased expression of ACSL4 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in increased expression of NCOA4 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in increased expression of NCOA4 protein]; NCOA4 protein affects the reaction [beryllium sulfate results in increased expression of PTGS2 mRNA] beryllium sulfate results in increased expression of NCOA4 mRNA; beryllium sulfate results in increased expression of NCOA4 protein |
CTD |
PMID:36843388 |
|
NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641 Ensembl chr16:7,366,542...7,409,641
|
|
G |
Nedd8 |
NEDD8 ubiquitin like modifier |
increases expression |
ISO |
beryllium sulfate results in increased expression of NEDD8 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr15:29,153,556...29,165,575
Ensembl chr15:29,153,556...29,166,160
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[beryllium sulfate co-treated with IFNG protein] results in increased expression of NFKB1 protein |
CTD |
PMID:10755711 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
ISO |
beryllium sulfate results in increased expression of NOS2 protein |
CTD |
PMID:33197057 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nova1 |
NOVA alternative splicing regulator 1 |
increases expression |
ISO |
beryllium sulfate results in increased expression of NOVA1 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 6:63,780,105...63,905,567
Ensembl chr 6:63,783,489...63,906,289
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase-1 |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of PDPK1 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr10:13,105,435...13,182,664
Ensembl chr10:13,105,498...13,174,623
|
|
G |
Phf19 |
PHD finger protein 19 |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of PHF19 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr 3:18,175,281...18,197,289
Ensembl chr 3:18,175,282...18,196,405
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
beryllium sulfate results in increased expression of PTGS2 mRNA; beryllium sulfate results in increased expression of PTGS2 protein [sodium bisulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in increased expression of PTGS2 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of PTGS2 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in increased expression of PTGS2 mRNA] |
CTD |
PMID:33197057 PMID:36843388 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rhoa |
ras homolog family member A |
increases expression |
ISO |
beryllium sulfate results in increased expression of RHOA mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rpl22 |
ribosomal protein L22 |
increases expression |
ISO |
beryllium sulfate results in increased expression of RPL22 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 5:162,835,241...162,843,394
Ensembl chr 5:162,833,740...162,843,368 Ensembl chr 7:162,833,740...162,843,368 Ensembl chr 4:162,833,740...162,843,368
|
|
G |
Rpl30 |
ribosomal protein L30 |
increases expression |
ISO |
beryllium sulfate results in increased expression of RPL30 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 7:65,648,266...65,651,401
Ensembl chr 7:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363 Ensembl chr 1:65,645,991...65,651,363
|
|
G |
Rpl37a |
ribosomal protein L37A |
increases expression |
ISO |
beryllium sulfate results in increased expression of RPL37A mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 9:74,298,843...74,300,926
|
|
G |
Rps7 |
ribosomal protein S7 |
increases expression |
ISO |
beryllium sulfate results in increased expression of RPS7 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 6:45,266,200...45,271,064
Ensembl chr 6:45,223,980...45,271,145 Ensembl chr 5:45,223,980...45,271,145
|
|
G |
RT1-CE16 |
RT1 class I, locus CE16 |
increases expression |
ISO |
beryllium sulfate results in increased expression of HLA-A mRNA |
CTD |
PMID:16314022 |
|
NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563
|
|
G |
RT1-Db1 |
RT1 class II, locus Db1 |
increases response to substance increases expression |
ISO |
HLA-DRB1 protein mutant form results in increased susceptibility to beryllium sulfate beryllium sulfate results in increased expression of HLA-DRB1 mRNA |
CTD |
PMID:16272364 PMID:16314022 |
|
NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258
|
|
G |
RT1-Hb-ps1 |
RT1 class II, locus Hb, pseudogene 1 |
affects binding |
ISO |
beryllium sulfate binds to HLA-DPB1 protein |
CTD |
PMID:11423174 |
|
NCBI chr20:4,775,598...4,779,590
Ensembl chr20:4,774,650...4,780,618
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
multiple interactions |
ISO |
beryllium sulfate promotes the reaction [RUNX1 protein binds to CCL3 promoter] |
CTD |
PMID:16314022 |
|
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
|
|
G |
Serpinb2 |
serpin family B member 2 |
increases expression |
ISO |
beryllium sulfate results in increased expression of SERPINB2 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Sftpd |
surfactant protein D |
increases expression |
ISO |
beryllium sulfate results in increased expression of SFTPD mRNA |
CTD |
PMID:16314022 |
|
NCBI chr16:17,046,491...17,058,968
Ensembl chr16:17,046,483...17,059,927
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
multiple interactions decreases expression |
ISO |
[sodium bisulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in decreased expression of SLC7A11 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of SLC7A11 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of SLC7A11 mRNA] |
CTD |
PMID:36843388 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Tat |
tyrosine aminotransferase |
multiple interactions |
EXP |
beryllium sulfate inhibits the reaction [Hydrocortisone results in increased expression of TAT protein] |
CTD |
PMID:6120038 |
|
NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
|
|
G |
Thsd7a |
thrombospondin type 1 domain containing 7A |
decreases expression increases expression |
ISO |
beryllium sulfate results in decreased expression of THSD7A mRNA beryllium sulfate results in increased expression of THSD7A mRNA |
CTD |
PMID:35679967 |
|
NCBI chr 4:40,461,124...40,899,345
Ensembl chr 4:40,460,814...40,899,583
|
|
G |
Tmsb4x |
thymosin beta 4, X-linked |
increases expression |
ISO |
beryllium sulfate results in increased expression of TMSB4X mRNA |
CTD |
PMID:16314022 |
|
NCBI chr X:27,144,666...27,146,667
Ensembl chr X:27,128,610...27,146,667 Ensembl chr10:27,128,610...27,146,667
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
beryllium sulfate results in increased expression of TNF mRNA; beryllium sulfate results in increased expression of TNF protein beryllium sulfate promotes the reaction [IFNG protein results in increased expression of TNF protein] |
CTD |
PMID:10755710 PMID:10755711 PMID:33197057 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
beryllium sulfate promotes the reaction [TP53 protein binds to CDKN1A promoter] beryllium sulfate results in increased expression of TP53 protein |
CTD |
PMID:17395767 PMID:20974702 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Wnt4 |
Wnt family member 4 |
increases expression |
ISO |
beryllium sulfate results in increased expression of WNT4 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Zfp77 |
zinc finger protein 77 |
increases expression |
ISO |
beryllium sulfate results in increased expression of ZNF77 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 7:7,269,879...7,316,286
Ensembl chr 7:7,269,927...7,286,051
|
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
ISO |
Calcium Carbonate results in decreased expression of BGLAP protein |
CTD |
PMID:2027271 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Capn1 |
calpain 1 |
increases activity |
ISO |
Calcium Carbonate analog results in increased activity of CAPN1 protein |
CTD |
PMID:24412303 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
Calcium Carbonate analog results in increased activity of CASP3 protein |
CTD |
PMID:24412303 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Calcium Carbonate analog results in increased expression of DDIT3 |
CTD |
PMID:24412303 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Pth |
parathyroid hormone |
affects expression decreases expression |
ISO |
Calcium Carbonate affects the expression of PTH protein Calcium Carbonate results in decreased expression of PTH protein |
CTD |
PMID:1752077 PMID:2027271 PMID:3826069 PMID:7891547 PMID:8481062 PMID:16006300 More...
|
|
NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
decreases expression |
ISO |
Calcium Carbonate results in decreased expression of PTHLH protein |
CTD |
PMID:16006300 |
|
NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
ISO |
Calcium Carbonate results in decreased expression of SPP1 protein |
CTD |
PMID:17977878 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
|
G |
Adam10 |
ADAM metallopeptidase domain 10 |
increases expression |
EXP |
Calcium Chloride results in increased expression of ADAM10 mRNA; Calcium Chloride results in increased expression of ADAM10 protein |
CTD |
PMID:20621845 |
|
NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
increases expression |
EXP |
Calcium Chloride results in increased expression of ADAM17 mRNA; Calcium Chloride results in increased expression of ADAM17 protein |
CTD |
PMID:20621845 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression |
ISO |
Calcium Chloride results in increased expression of ALPL mRNA |
CTD |
PMID:25824407 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apoc3 |
apolipoprotein C3 |
increases expression |
ISO |
Calcium Chloride results in increased expression of APOC3 protein |
CTD |
PMID:25824407 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
increases expression |
ISO |
Calcium Chloride results in increased expression of ATP5PF protein |
CTD |
PMID:25824407 |
|
NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119
|
|
G |
Bag4 |
BAG cochaperone 4 |
increases expression |
ISO |
Calcium Chloride results in increased expression of BAG4 protein |
CTD |
PMID:25824407 |
|
NCBI chr16:66,288,678...66,305,893
Ensembl chr16:66,288,678...66,308,663
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
ISO |
Calcium Chloride results in increased expression of BGLAP mRNA |
CTD |
PMID:25824407 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bicd2 |
BICD cargo adaptor 2 |
increases expression |
ISO |
Calcium Chloride results in increased expression of BICD2 protein |
CTD |
PMID:25824407 |
|
NCBI chr17:15,259,773...15,304,889
Ensembl chr17:15,259,773...15,304,889
|
|
G |
Calm3 |
calmodulin 3 |
multiple interactions |
ISO |
Calcium Chloride inhibits the reaction [CALM3 protein binds to and results in decreased activity of UBE3B protein] |
CTD |
PMID:28003368 |
|
NCBI chr 1:77,590,668...77,597,776
Ensembl chr 1:77,589,230...77,592,207
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
EXP |
cordycepin inhibits the reaction [Calcium Chloride results in increased cleavage of CASP3 protein] |
CTD |
PMID:36731150 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
EXP |
Calcium Chloride results in increased cleavage of CASP9 protein cordycepin inhibits the reaction [Calcium Chloride results in increased cleavage of CASP9 protein] |
CTD |
PMID:36731150 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Casr |
calcium-sensing receptor |
multiple interactions increases activity |
ISO |
Calcium Chloride promotes the reaction [Calcium results in increased phosphorylation of CASR protein] Calcium Chloride results in increased activity of CASR protein |
CTD |
PMID:16316325 PMID:17376781 |
|
NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases phosphorylation increases expression multiple interactions |
ISO |
Calcium Chloride results in increased phosphorylation of CCL2 protein Calcium Chloride results in increased expression of CCL2 mRNA; Calcium Chloride results in increased expression of CCL2 protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of CCL2 protein]; Resveratrol inhibits the reaction [Calcium Chloride results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [Calcium Chloride results in increased phosphorylation of CCL2 protein] |
CTD |
PMID:21530968 PMID:22728078 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cct6a |
chaperonin containing TCP1 subunit 6A |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of CCT6A protein |
CTD |
PMID:25824407 |
|
NCBI chr12:26,872,736...26,883,125
Ensembl chr12:26,872,574...26,883,337
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions increases expression |
ISO |
resveratrol inhibits the reaction [Calcium Chloride results in increased expression of CD68 mRNA] |
CTD |
PMID:21530968 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
EXP |
Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN1B protein] |
CTD |
PMID:12189186 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
EXP |
Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A mRNA]; Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A protein] |
CTD |
PMID:12189186 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases activity |
ISO |
Calcium Chloride results in increased activity of CEBPA protein |
CTD |
PMID:17214633 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Clec3b |
C-type lectin domain family 3, member B |
increases expression |
ISO |
Calcium Chloride results in increased expression of CLEC3B protein |
CTD |
PMID:25824407 |
|
NCBI chr 8:122,810,120...122,815,837
Ensembl chr 8:122,810,149...122,815,835
|
|
G |
Clic3 |
chloride intracellular channel 3 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of CLIC3 protein |
CTD |
PMID:25824407 |
|
NCBI chr 3:8,271,416...8,274,023
Ensembl chr 3:8,272,097...8,274,018
|
|
G |
Cmtm6 |
CKLF-like MARVEL transmembrane domain containing 6 |
increases expression |
ISO |
Calcium Chloride results in increased expression of CMTM6 protein |
CTD |
PMID:25824407 |
|
NCBI chr 8:114,422,934...114,441,034
Ensembl chr 8:114,422,921...114,441,033
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Calcium Chloride results in increased expression of COL1A1 mRNA |
CTD |
PMID:25824407 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
increases expression |
ISO |
Calcium Chloride results in increased expression of COL8A1 protein |
CTD |
PMID:25824407 |
|
NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
|
|
G |
Cops3 |
COP9 signalosome subunit 3 |
increases expression |
ISO |
Calcium Chloride results in increased expression of COPS3 protein |
CTD |
PMID:25824407 |
|
NCBI chr10:44,618,115...44,652,807
Ensembl chr10:44,618,115...44,641,597
|
|
G |
Cst3 |
cystatin C |
increases expression |
ISO |
Calcium Chloride results in increased expression of CST3 protein |
CTD |
PMID:25824407 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Cthrc1 |
collagen triple helix repeat containing 1 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of CTHRC1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 7:70,122,474...70,132,756
Ensembl chr 7:70,122,474...70,132,756
|
|
G |
Ctsb |
cathepsin B |
increases expression multiple interactions |
ISO |
Calcium Chloride results in increased expression of CTSB protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of CTSB protein] |
CTD |
PMID:22728078 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsk |
cathepsin K |
increases expression multiple interactions |
ISO |
Calcium Chloride results in increased expression of CTSK protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of CTSK protein] |
CTD |
PMID:22728078 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Dcn |
decorin |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of DCN protein |
CTD |
PMID:25824407 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddx39b |
DExD-box helicase 39B |
increases expression |
ISO |
Calcium Chloride results in increased expression of DDX39B protein |
CTD |
PMID:25824407 |
|
NCBI chr20:3,547,702...3,585,064
Ensembl chr20:3,572,056...3,584,996
|
|
G |
Ehd2 |
EH-domain containing 2 |
increases expression |
ISO |
Calcium Chloride results in increased expression of EHD2 protein |
CTD |
PMID:25824407 |
|
NCBI chr 1:76,639,568...76,658,747
Ensembl chr 1:76,637,482...76,658,783
|
|
G |
F10 |
coagulation factor X |
multiple interactions |
ISO |
[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein; aspalathin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein]; nothofagin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein] |
CTD |
PMID:25325928 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F11 |
coagulation factor XI |
multiple interactions |
ISO |
[F11 protein co-treated with Calcium Chloride] results in increased activity of F9 protein |
CTD |
PMID:6604052 |
|
NCBI chr16:46,987,988...47,009,015
Ensembl chr16:46,986,107...47,008,437
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions |
ISO |
[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein; aspalathin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein]; nothofagin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein] |
CTD |
PMID:25325928 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F5 |
coagulation factor V |
multiple interactions |
ISO |
[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein; aspalathin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein]; nothofagin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein] |
CTD |
PMID:25325928 |
|
NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317
|
|
G |
F9 |
coagulation factor IX |
multiple interactions |
ISO |
[F11 protein co-treated with Calcium Chloride] results in increased activity of F9 protein |
CTD |
PMID:6604052 |
|
NCBI chr X:138,352,334...138,396,835
Ensembl chr X:138,352,298...138,396,835
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
Calcium Chloride results in increased expression of FYN protein |
CTD |
PMID:25824407 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Git1 |
GIT ArfGAP 1 |
increases expression |
ISO |
Calcium Chloride results in increased expression of GIT1 protein |
CTD |
PMID:25824407 |
|
NCBI chr10:62,342,082...62,356,379
Ensembl chr10:62,342,299...62,356,373
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
EXP |
[manganese chloride co-treated with Calcium Chloride] results in increased secretion of GNRH1 protein |
CTD |
PMID:18603625 |
|
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Gpr89b |
G protein-coupled receptor 89B |
increases expression |
ISO |
Calcium Chloride results in increased expression of GPR89B protein |
CTD |
PMID:25824407 |
|
NCBI chr 2:184,408,136...184,445,560
Ensembl chr 2:184,401,438...184,445,584
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions increases expression |
ISO |
Quercetin inhibits the reaction [Calcium Chloride results in increased expression of GPX1 mRNA]; resveratrol inhibits the reaction [Calcium Chloride results in increased expression of GPX1 mRNA] |
CTD |
PMID:21530968 PMID:24337353 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions increases expression |
ISO |
Quercetin inhibits the reaction [Calcium Chloride results in increased expression of GPX3 mRNA]; resveratrol inhibits the reaction [Calcium Chloride results in increased expression of GPX3 mRNA] |
CTD |
PMID:21530968 PMID:24337353 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA] |
CTD |
PMID:21443188 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of HTRA1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression multiple interactions |
ISO |
Calcium Chloride results in increased expression of ICAM1 mRNA resveratrol inhibits the reaction [Calcium Chloride results in increased expression of ICAM1 mRNA] |
CTD |
PMID:21530968 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ift27 |
intraflagellar transport 27 |
increases expression |
ISO |
Calcium Chloride results in increased expression of IFT27 protein |
CTD |
PMID:25824407 |
|
NCBI chr 7:109,738,622...109,754,416
Ensembl chr 7:109,738,622...109,754,416
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
ISO EXP |
Calcium Chloride results in increased expression of IL1B protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of IL1B protein] |
CTD |
PMID:22728078 PMID:36731150 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Itih1 |
inter-alpha trypsin inhibitor, heavy chain 1 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [ITIH1 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr16:6,122,246...6,136,363
Ensembl chr16:6,122,248...6,136,363
|
|
G |
Itih2 |
inter-alpha-trypsin inhibitor heavy chain 2 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [ITIH2 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr17:68,375,574...68,411,849
Ensembl chr17:68,375,567...68,411,841
|
|
G |
Klk8 |
kallikrein related-peptidase 8 |
increases activity |
ISO |
Calcium Chloride results in increased activity of KLK8 protein |
CTD |
PMID:16800733 |
|
NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
increases expression |
ISO |
Calcium Chloride results in increased expression of LASP1 protein |
CTD |
PMID:25824407 |
|
NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292
|
|
G |
Lrrfip1 |
LRR binding FLII interacting protein 1 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of LRRFIP1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 9:91,592,032...91,720,250
Ensembl chr 9:91,643,197...91,720,250
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP |
Calcium Chloride results in increased phosphorylation of MAPK1 protein [4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK1 protein; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:21215118 PMID:33621091 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression multiple interactions increases phosphorylation |
ISO EXP |
Calcium Chloride results in increased expression of MAPK3 protein [4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK3 protein; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK3 protein] Calcium Chloride results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:21215118 PMID:25824407 PMID:33621091 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression increases activity multiple interactions |
EXP ISO |
Calcium Chloride results in increased expression of MMP2 mRNA; Calcium Chloride results in increased expression of MMP2 protein Calcium Chloride results in increased activity of MMP2 protein Quercetin inhibits the reaction [Calcium Chloride results in increased activity of MMP2 protein]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of MMP2 mRNA]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of MMP2 protein]; resveratrol inhibits the reaction [Calcium Chloride results in increased activity of MMP2 protein] Calcium Chloride inhibits the reaction [2,3-dihydroxybenzoic acid results in decreased activity of MMP2 protein]; Calcium Chloride inhibits the reaction [Deferoxamine results in decreased activity of MMP2 protein]; Calcium Chloride inhibits the reaction [Ferrichrome results in decreased activity of MMP2 protein]; Calcium Chloride inhibits the reaction [rhodotorulic acid results in decreased activity of MMP2 protein] |
CTD |
PMID:10086886 PMID:16159824 PMID:20621845 PMID:21530968 PMID:22728078 PMID:24337353 More...
|
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression increases activity multiple interactions |
EXP ISO |
Calcium Chloride results in increased expression of MMP9 mRNA; Calcium Chloride results in increased expression of MMP9 protein Calcium Chloride results in increased activity of MMP9 protein Quercetin inhibits the reaction [Calcium Chloride results in increased activity of MMP9 protein]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of MMP9 mRNA]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of MMP9 protein]; resveratrol inhibits the reaction [Calcium Chloride results in increased activity of MMP9 protein] |
CTD |
PMID:20621845 PMID:21530968 PMID:22728078 PMID:24337353 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
Calcium Chloride inhibits the reaction [Azoxymethane results in increased expression of MYC mRNA]; Calcium Chloride inhibits the reaction [Azoxymethane results in increased expression of MYC protein] |
CTD |
PMID:12189186 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
increases expression multiple interactions |
ISO |
Calcium Chloride results in increased expression of NCF1 mRNA; Calcium Chloride results in increased expression of NCF1 protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of NCF1 mRNA]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of NCF1 protein] |
CTD |
PMID:24337353 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
EXP |
Calcium Chloride promotes the reaction [NOS1 protein results in increased reduction of Trinitrotoluene] |
CTD |
PMID:15223068 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
ISO |
Calcium Chloride results in increased expression of NOS2 mRNA Quercetin inhibits the reaction [Calcium Chloride results in increased expression of NOS2 mRNA] |
CTD |
PMID:24337353 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nt5c |
5', 3'-nucleotidase, cytosolic |
increases expression |
ISO |
Calcium Chloride results in increased expression of NT5C protein |
CTD |
PMID:25824407 |
|
NCBI chr10:100,739,591...100,742,276
Ensembl chr10:100,739,588...100,741,954
|
|
G |
Nxn |
nucleoredoxin |
increases expression |
ISO |
Calcium Chloride results in increased expression of NXN protein |
CTD |
PMID:25824407 |
|
NCBI chr10:61,109,322...61,247,578
Ensembl chr10:61,110,020...61,248,251
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [PON1 protein results in increased hydrolysis of Paraoxon] |
CTD |
PMID:16052486 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Postn |
periostin |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of POSTN protein |
CTD |
PMID:25824407 |
|
NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099
|
|
G |
Ppid |
peptidylprolyl isomerase D |
increases expression |
ISO |
Calcium Chloride results in increased expression of PPID mRNA; Calcium Chloride results in increased expression of PPID protein |
CTD |
PMID:18614807 |
|
NCBI chr 2:164,727,803...164,740,168
Ensembl chr 2:164,727,779...164,740,221
|
|
G |
Psen2 |
presenilin 2 |
increases expression |
ISO |
Calcium Chloride results in increased expression of PSEN2 protein |
CTD |
PMID:25824407 |
|
NCBI chr13:91,967,506...91,993,240
Ensembl chr13:91,967,983...91,993,174
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of RAD50 protein |
CTD |
PMID:25824407 |
|
NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396
|
|
G |
Reck |
reversion-inducing-cysteine-rich protein with kazal motifs |
increases expression |
ISO |
Calcium Chloride results in increased expression of RECK protein |
CTD |
PMID:25824407 |
|
NCBI chr 5:58,102,961...58,169,516
Ensembl chr 5:58,102,981...58,169,502
|
|
G |
S100a13 |
S100 calcium binding protein A13 |
multiple interactions |
ISO |
[Calcium Chloride co-treated with cuprous chloride] binds to and affects the folding of S100A13 protein; Calcium Chloride binds to and affects the folding of S100A13 protein |
CTD |
PMID:16766622 |
|
NCBI chr 2:175,999,439...176,005,933
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
increases expression |
ISO |
Calcium Chloride results in increased expression of S100A8 mRNA; Calcium Chloride results in increased expression of S100A8 protein |
CTD |
PMID:17214633 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
Calcium Chloride results in increased expression of S100A9 mRNA; Calcium Chloride results in increased expression of S100A9 protein |
CTD |
PMID:17214633 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Shc1 |
SHC adaptor protein 1 |
increases expression |
ISO |
Calcium Chloride results in increased expression of SHC1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases activity multiple interactions |
ISO |
Calcium Chloride results in increased activity of SOD2 protein Quercetin inhibits the reaction [Calcium Chloride results in increased activity of SOD2 protein] |
CTD |
PMID:24337353 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Stat6 |
signal transducer and activator of transcription 6 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of STAT6 protein |
CTD |
PMID:25824407 |
|
NCBI chr 7:63,480,229...63,497,551
Ensembl chr 7:63,479,642...63,498,495
|
|
G |
Syn1 |
synapsin I |
multiple interactions |
EXP |
[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of SYN1 protein; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of SYN1 protein] |
CTD |
PMID:33621091 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of TGFB1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression multiple interactions |
ISO |
Calcium Chloride results in decreased expression of TIMP1 mRNA Quercetin inhibits the reaction [Calcium Chloride results in decreased expression of TIMP1 mRNA] |
CTD |
PMID:22728078 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
Quercetin inhibits the reaction [Calcium Chloride results in increased expression of TNF protein]; resveratrol inhibits the reaction [Calcium Chloride results in increased expression of TNF mRNA] cordycepin inhibits the reaction [Calcium Chloride results in increased expression of TNF protein] Calcium Chloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein] Calcium Chloride results in increased expression of TNF mRNA; Calcium Chloride results in increased expression of TNF protein |
CTD |
PMID:21530968 PMID:22728078 PMID:36416909 PMID:36731150 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [ITIH1 protein binds to TNFAIP6 protein]; Calcium Chloride promotes the reaction [ITIH2 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases activity |
ISO EXP |
Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; Ionomycin promotes the reaction [Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]] Ionomycin inhibits the reaction [Calcium Chloride results in increased activity of TRPV1 protein]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [Calcium Chloride results in increased activity of TRPV1 protein]; resiniferatoxin promotes the reaction [Calcium Chloride results in increased activity of TRPV1 protein] |
CTD |
PMID:19553475 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Ube3b |
ubiquitin protein ligase E3B |
multiple interactions |
ISO |
Calcium Chloride inhibits the reaction [CALM3 protein binds to and results in decreased activity of UBE3B protein] |
CTD |
PMID:28003368 |
|
NCBI chr12:42,183,756...42,230,094
Ensembl chr12:42,183,760...42,230,094
|
|
G |
Uqcrfs1 |
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
decreases phosphorylation multiple interactions |
EXP |
Calcium Chloride results in decreased phosphorylation of UQCRFS1 protein [oxophenylarsine co-treated with Calcium Chloride] results in decreased phosphorylation of UQCRFS1 protein; [tert-Butylhydroperoxide co-treated with Calcium Chloride] results in decreased phosphorylation of UQCRFS1 protein; Cyclosporine inhibits the reaction [[oxophenylarsine co-treated with Calcium Chloride] results in decreased phosphorylation of UQCRFS1 protein]; Cyclosporine inhibits the reaction [[tert-Butylhydroperoxide co-treated with Calcium Chloride] results in decreased phosphorylation of UQCRFS1 protein] |
CTD |
PMID:16023995 |
|
NCBI chr17:33,977,908...33,982,478
Ensembl chr17:33,977,921...33,982,479
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
Calcium Chloride results in increased expression of VEGFA mRNA resveratrol inhibits the reaction [Calcium Chloride results in increased expression of VEGFA mRNA] |
CTD |
PMID:21530968 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
SIRT1 protein inhibits the reaction [Calcium Oxalate results in increased expression of BAX protein] |
CTD |
PMID:34333021 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
SIRT1 protein inhibits the reaction [Calcium Oxalate results in decreased expression of BCL2 protein] |
CTD |
PMID:34333021 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO |
SIRT1 protein inhibits the reaction [Calcium Oxalate results in increased cleavage of CASP3 protein] |
CTD |
PMID:34333021 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions decreases expression |
EXP |
2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of CAT protein] |
CTD |
PMID:37454925 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions |
EXP |
Calcium Oxalate results in decreased expression of CCL2 protein 2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of CCL2 protein]; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CCL2 mRNA; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CCL2 protein; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CCL2 mRNA]; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CCL2 protein] |
CTD |
PMID:37414240 PMID:37454925 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions decreases expression |
EXP |
2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of CD44 protein]; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CD44 mRNA; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CD44 protein; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CD44 mRNA]; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CD44 protein] |
CTD |
PMID:37414240 PMID:37454925 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions increases expression |
EXP |
2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in increased expression of NOX2 protein] |
CTD |
PMID:37454925 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp2c7 |
cytochrome P450, family 2, subfamily c, polypeptide 7 |
multiple interactions |
EXP |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CYP2C9 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CYP2C9 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr 1:237,332,641...237,388,714
Ensembl chr 1:237,332,659...237,388,709
|
|
G |
Hdac1 |
histone deacetylase 1 |
multiple interactions |
EXP |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC1 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC1 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hdac2 |
histone deacetylase 2 |
multiple interactions |
EXP |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC2 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC2 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac3 |
histone deacetylase 3 |
multiple interactions |
EXP |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC3 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC3 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856
|
|
G |
Hdac8 |
histone deacetylase 8 |
multiple interactions |
EXP |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC8 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC8 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
phenyl-N-tert-butylnitrone inhibits the reaction [Calcium Oxalate results in increased expression of HMOX1 protein] |
CTD |
PMID:34333021 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
increases expression multiple interactions |
EXP |
Calcium Oxalate results in increased expression of ITPR1 protein Losartan inhibits the reaction [Calcium Oxalate results in increased expression of ITPR1 protein] |
CTD |
PMID:37454925 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Itpr2 |
inositol 1,4,5-trisphosphate receptor, type 2 |
multiple interactions increases expression |
EXP |
Losartan inhibits the reaction [Calcium Oxalate results in increased expression of ITPR2 protein] |
CTD |
PMID:37454925 |
|
NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164
|
|
G |
Itpr3 |
inositol 1,4,5-trisphosphate receptor, type 3 |
increases expression |
EXP |
Calcium Oxalate results in increased expression of ITPR3 protein |
CTD |
PMID:37454925 |
|
NCBI chr20:5,136,968...5,202,339
Ensembl chr20:5,136,441...5,202,337
|
|
G |
Nox4 |
NADPH oxidase 4 |
increases expression multiple interactions |
EXP |
Calcium Oxalate results in increased expression of NOX4 protein 2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in increased expression of NOX4 protein] |
CTD |
PMID:37454925 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
ISO |
phenyl-N-tert-butylnitrone inhibits the reaction [Calcium Oxalate results in decreased expression of SIRT1 protein]; SIRT1 protein inhibits the reaction [Calcium Oxalate results in decreased expression of BCL2 protein]; SIRT1 protein inhibits the reaction [Calcium Oxalate results in increased cleavage of CASP3 protein]; SIRT1 protein inhibits the reaction [Calcium Oxalate results in increased expression of BAX protein] |
CTD |
PMID:34333021 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
EXP |
2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of SOD1 protein] |
CTD |
PMID:37454925 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions decreases expression |
EXP |
2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of SPP1 protein]; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of SPP1 mRNA; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of SPP1 protein; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of SPP1 mRNA]; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of SPP1 protein] |
CTD |
PMID:37414240 PMID:37454925 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
calcium phosphate results in increased expression of CXCL10 protein |
CTD |
PMID:14600836 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
ISO |
calcium phosphate results in increased expression of CXCL12 protein |
CTD |
PMID:14600836 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in decreased expression of ABCA1 mRNA Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of ABCA1 mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO EXP |
Rosuvastatin Calcium inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid] [Cyclosporine results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium; [Glyburide results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium; [troglitazone results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium |
CTD |
PMID:15901796 PMID:19853032 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions affects secretion increases expression |
ISO EXP |
ABCC2 protein binds to and results in increased uptake of Rosuvastatin Calcium analog; Rosuvastatin Calcium analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein] ABCC2 protein affects the secretion of Rosuvastatin Calcium [Benzbromarone results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; [Probenecid results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; [Sulfasalazine results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; ABCC2 protein binds to and results in increased uptake of Rosuvastatin Calcium analog; Rosuvastatin Calcium analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Rosuvastatin Calcium promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein] Rosuvastatin Calcium results in increased expression of ABCC2 protein |
CTD |
PMID:19853032 PMID:23562342 PMID:24909372 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
Rosuvastatin Calcium results in increased expression of ABCC3 protein |
CTD |
PMID:24909372 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of ABCG1 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions increases activity |
EXP ISO |
[Novobiocin results in decreased activity of ABCG2 protein] which results in decreased secretion of Rosuvastatin Calcium Rosuvastatin Calcium results in increased activity of ABCG2 protein |
CTD |
PMID:19853032 PMID:30083819 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
[Piracetam co-treated with Rosuvastatin Calcium] inhibits the reaction [[Sodium Chloride, Dietary co-treated with Cholesterol, Dietary co-treated with Coconut Oil] results in increased activity of ACHE protein]; Rosuvastatin Calcium inhibits the reaction [[Sodium Chloride, Dietary co-treated with Cholesterol, Dietary co-treated with Coconut Oil] results in increased activity of ACHE protein] |
CTD |
PMID:28441890 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation |
EXP |
Rosuvastatin Calcium affects the phosphorylation of AKT1 protein |
CTD |
PMID:27815113 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions increases expression |
ISO |
Niacin promotes the reaction [Rosuvastatin Calcium results in increased expression of APOA1 protein] |
CTD |
PMID:12767421 PMID:15539964 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of APOB protein |
CTD |
PMID:15539964 PMID:18702965 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of BAX mRNA] |
CTD |
PMID:32007421 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of BCL2 protein |
CTD |
PMID:20852871 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
C3 |
complement C3 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of C3 mRNA |
CTD |
PMID:32771489 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Casp3 |
caspase 3 |
increases activity increases expression |
ISO |
Rosuvastatin Calcium results in increased activity of CASP3 protein Rosuvastatin Calcium results in increased expression of CASP3 protein |
CTD |
PMID:21478229 PMID:32771489 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
increases activity multiple interactions |
EXP |
Rosuvastatin Calcium results in increased activity of CAT protein [Rosuvastatin Calcium co-treated with Isoproterenol] inhibits the reaction [Interleukin-6 results in increased expression of CAT protein]; Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in decreased activity of CAT protein] |
CTD |
PMID:20146376 PMID:32007421 PMID:35130744 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
EXP |
Rosuvastatin Calcium results in decreased expression of CCL2 mRNA |
CTD |
PMID:15681303 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Creb5 |
cAMP responsive element binding protein 5 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of CREB5 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr 4:82,393,091...82,794,320
Ensembl chr 4:82,393,730...82,790,325
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [CRP protein results in decreased expression of NOS3] |
CTD |
PMID:21562509 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions decreases expression |
EXP |
[[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species |
CTD |
PMID:21562509 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions decreases expression |
ISO EXP |
Rosuvastatin Calcium inhibits the reaction [Nitroglycerin results in increased expression of CYBB mRNA] [[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species |
CTD |
PMID:16633368 PMID:21562509 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of ESR1 protein |
CTD |
PMID:32771489 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in increased expression of GCLC mRNA [Tetradecanoylphorbol Acetate co-treated with Rosuvastatin Calcium] results in increased expression of GCLC mRNA |
CTD |
PMID:18154958 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gpr183 |
G protein-coupled receptor 183 |
multiple interactions increases expression |
ISO |
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in increased expression of GPR183 mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559
|
|
G |
Gzmk |
granzyme K |
multiple interactions increases expression |
ISO |
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in increased expression of GZMK mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 2:44,840,811...44,848,829
Ensembl chr 2:44,840,811...44,848,894
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
increases secretion |
ISO |
HNF4A protein results in increased secretion of Rosuvastatin Calcium |
CTD |
PMID:27160211 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Il18rap |
interleukin 18 receptor accessory protein |
decreases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in decreased expression of IL18RAP mRNA Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of IL18RAP mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 9:42,768,112...42,800,964
Ensembl chr 9:42,768,220...42,800,959
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
EXP |
Rosuvastatin Calcium results in decreased expression of IL1B mRNA |
CTD |
PMID:15681303 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Rosuvastatin Calcium results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj15 |
potassium inwardly-rectifying channel, subfamily J, member 15 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of KCNJ15 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr11:34,577,397...34,621,725
Ensembl chr11:34,577,363...34,621,952
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of KDR protein] |
CTD |
PMID:27097221 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Mb |
myoglobin |
affects expression |
EXP |
Rosuvastatin Calcium affects the expression of MB protein |
CTD |
PMID:27815113 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mstn |
myostatin |
increases expression |
ISO |
Rosuvastatin Calcium results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:32007421 PMID:35130744 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP |
Rosuvastatin Calcium results in increased expression of NOS2 mRNA Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of NOS2 mRNA] |
CTD |
PMID:21443142 PMID:32007421 PMID:35130744 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases expression affects response to substance |
ISO EXP |
Rosuvastatin Calcium inhibits the reaction [CRP protein results in decreased expression of NOS3]; Rosuvastatin Calcium results in increased phosphorylation of and results in increased activity of NOS3 protein Rosuvastatin Calcium results in increased expression of NOS3 mRNA NOS3 protein affects the susceptibility to Rosuvastatin Calcium |
CTD |
PMID:12354446 PMID:15681303 PMID:18162361 PMID:21562509 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Orm1 |
orosomucoid 1 |
multiple interactions decreases expression |
ISO |
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of ORM1 mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PECAM1 protein] |
CTD |
PMID:27097221 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Selp |
selectin P |
decreases expression |
EXP |
Rosuvastatin Calcium results in decreased expression of SELP mRNA |
CTD |
PMID:15681303 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Serpine2 |
serpin family E member 2 |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of SERPINE2 protein]; Rosuvastatin Calcium inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein] |
CTD |
PMID:27097221 |
|
NCBI chr 9:81,124,746...81,188,866
Ensembl chr 9:81,124,804...81,188,826
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions increases uptake decreases expression affects transport |
EXP ISO |
Fusidic Acid inhibits the reaction [SLCO1A4 protein results in increased uptake of Rosuvastatin Calcium] diosmetin inhibits the reaction [SLCO1A2 protein results in increased uptake of Rosuvastatin Calcium] Rosuvastatin Calcium results in decreased expression of SLCO1A4 protein SLCO1A4 protein affects the transport of Rosuvastatin Calcium |
CTD |
PMID:19833843 PMID:24909372 PMID:26888941 PMID:28867436 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions increases uptake |
EXP ISO |
Fusidic Acid inhibits the reaction [SLCO1B2 protein results in increased uptake of Rosuvastatin Calcium] Fusidic Acid inhibits the reaction [SLCO1B3 protein results in increased uptake of Rosuvastatin Calcium] |
CTD |
PMID:26888941 PMID:31299240 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
increases uptake multiple interactions |
ISO |
SLCO2B1 protein results in increased uptake of Rosuvastatin Calcium Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Rosuvastatin Calcium] |
CTD |
PMID:24285294 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases expression |
EXP |
[[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species |
CTD |
PMID:21562509 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Tff1 |
trefoil factor 1 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of TFF1 mRNA |
CTD |
PMID:32771489 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases expression |
ISO EXP |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of TGFB1 protein]; Rosuvastatin Calcium inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein] Rosuvastatin Calcium results in decreased expression of TGFB1 mRNA |
CTD |
PMID:15681303 PMID:27097221 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
EXP |
Rosuvastatin Calcium results in decreased expression of TNF mRNA Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of TNF protein] |
CTD |
PMID:15681303 PMID:32007421 PMID:35130744 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
EXP |
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of TNNI3 protein] |
CTD |
PMID:32007421 PMID:35130744 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
G |
Vnn3 |
vanin 3 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of VNN3P mRNA |
CTD |
PMID:18192897 |
|
NCBI chr 1:21,571,364...21,583,626
Ensembl chr 1:21,571,364...21,583,626
|
|
G |
Wt1 |
WT1 transcription factor |
increases expression |
EXP |
Rosuvastatin Calcium results in increased expression of WT1 mRNA |
CTD |
PMID:21443142 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|
|
G |
Dnm1l |
dynamin 1-like |
increases expression |
ISO |
tricalcium phosphate results in increased expression of DNM1L protein |
CTD |
PMID:37678662 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression |
ISO |
tricalcium phosphate results in decreased expression of HMOX1 protein |
CTD |
PMID:37678662 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions affects localization |
ISO |
Acetylcysteine inhibits the reaction [tricalcium phosphate affects the localization of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [tricalcium phosphate results in increased expression of MAP1LC3B protein] |
CTD |
PMID:37678662 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mfn2 |
mitofusin 2 |
decreases expression |
ISO |
tricalcium phosphate results in decreased expression of MFN2 protein |
CTD |
PMID:37678662 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mlkl |
mixed lineage kinase domain like pseudokinase |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [tricalcium phosphate results in increased phosphorylation of MLKL protein]; N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide inhibits the reaction [tricalcium phosphate results in increased phosphorylation of MLKL protein]; necrostatin-1 inhibits the reaction [tricalcium phosphate results in increased phosphorylation of MLKL protein] |
CTD |
PMID:37678662 |
|
NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression |
ISO |
tricalcium phosphate results in decreased expression of NFE2L2 protein |
CTD |
PMID:37678662 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression |
ISO |
tricalcium phosphate results in decreased expression of NQO1 protein |
CTD |
PMID:37678662 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [tricalcium phosphate results in increased expression of PINK1 protein]; tricalcium phosphate results in increased expression of and results in increased localization of PINK1 protein |
CTD |
PMID:37678662 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
tricalcium phosphate results in increased phosphorylation of RIPK1 protein Acetylcysteine inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK1 protein]; N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK1 protein]; necrostatin-1 inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK1 protein] |
CTD |
PMID:37678662 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK3 protein]; N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK3 protein]; necrostatin-1 inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK3 protein] |
CTD |
PMID:37678662 |
|
NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression multiple interactions |
ISO |
tricalcium phosphate results in decreased expression of SQSTM1 protein Acetylcysteine inhibits the reaction [tricalcium phosphate results in decreased expression of SQSTM1 protein] |
CTD |
PMID:37678662 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression |
ISO |
tricalcium phosphate results in decreased expression of TXN1 protein |
CTD |
PMID:37678662 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression |
ISO |
tricalcium phosphate results in increased expression of TXNIP protein |
CTD |
PMID:37678662 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|